

Supplemental information:

SI Methods

Cell lines and reagents

Human ovarian serous adenocarcinoma cell lines (A224, OVCA429, SKOV3 etc.) and human monocytic leukemia cell line THP-1 were grown in RPMI1640 supplemented with 10% FBS and penicillin/streptomycin (Invitrogen). HUVECs (Lonza) were grown in EBM supplemented with 2% FBS and EGM-2 SingleQuots (Lonza) as primary culture and used within 6 passages. All cells were maintained in exponential growth phase at 37°C in 5% CO₂.

To generate conditioned media from ovarian tumor cells, 1 × 10⁶ cells were seeded in a T75 flask with RPMI1640 + 10% FBS overnight. The next day, culture medium was substituted by basal medium (EBM + 0.5% FBS for HUVECs experiments or RPMI1640 + 0.5% FBS for THP-1 experiments) for an additional 24 hours. The conditioned media were filtered through a low protein binding 0.45 µm PVDF filter (Millipore) and stored in a -80 °C freezer before use.

Antibodies were purchased from the following commercial sources: Sigma-Aldrich (FGF18), Santa Cruz Biotechnology (murine CD31), R&D Systems (FGFR4), AbD Serotec (F4/80), DAKO Cytomation (Ki-67 and human CD31), Thermo Scientific (CD163) and Cell Signaling Technology (all other antibodies).

Recombinant human FGF18 was purchased from Biovision. NF-κB pathway inhibitors QNZ (6-amino-4-(4-phenoxyphenylethylamino)quinazoline), SN-50 peptide (AAVALLPAVLLALLAPVQRKRQKLMP) and TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide) were purchased from Calbiochem. All the other chemicals including the pan-FGFR inhibitor PD173074 (1-t-butyl-3-(6-(3,5-dimethoxyphenyl)-

2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea) were purchased from Sigma-Aldrich.

In vitro assays for ovarian cancer cell lines and HUVECs

In vitro adherent cell proliferation assay was performed in 96-well plates with RPMI1640 + 1% FBS. Cell number was determined by CellTiter-Blue® Cell Viability Assay kit (Promega).

Boyden chamber based migration assay was performed in a 24-well cell culture insert with 8.0 μm pore size PET membrane (BD Biosciences). Cells were resuspended at 10,000 per mL in basal medium (RPMI1640 + 0.1% FBS for ovarian cancer cells or EBM + 0.5% FBS for HUVECs) and plated in triplicate in 350 μL into the upper chamber. The bottom chamber contained 500 μL of basal media with chemoattractant (2% FBS for ovarian cancer cells; 100 ng/mL rhFGF18 or tumor cell-derived conditioned medium with / without 100 nM PD173074 for HUVECs). After cells were plated for 3 hours, the insert was removed and wiped with a cotton swab to dislodge the non-migrated cells. Migrated cells on the underside were fixed and stained with Diff-Quick Stain Set (Dade Behring) and quantified by counting under 40 \times magnification (field covers >80% of the membrane).

Cell invasion assays were performed in BD BioCoat™ Growth Factor Reduced Matrigel Invasion Chambers with 8.0 μm pore size PET membrane. The same protocol as above was used and cells were allowed to invade for 24 hours before staining.

In vitro angiogenesis assay was performed by assessing tube formation of HUVECs as previously described (1). HUVECs (15,000 cells in 100 μL EBM2 + 0.5% FBS) were seeded in triplicate into a 96-well plate coated with Growth Factor Reduced Matrigel (BD Biosciences, 60 μL per well). To induce tube formation, 100 ng/mL rhFGF18 with / without 100 nM PD173074 was added. After incubation for 2.5 hours, HUVECs were stained by 1 μM Calcein-AM and

photographed under a fluorescent microscope (Ex/Em: 488/520 nm). Tube-like structures were quantified as total tube length by the skeleton plugin of ImageJ software (NCI).

In vitro assays for THP-1 cells

Migration of THP-1 cells were performed in 24-well cell culture insert with 3.0 μm pore size, FluoroBlok®, PET membrane (BD Biosciences). THP-1 cells were pre-labeled with 1 μM Calcein-AM and seeded into the insert in triplicate at 250,000 cells per 350 μL of RPMI1640 + 0.5% FBS. The inserts were placed into the wells containing tumor cell conditioned medium and incubated for 6 hours at 37°C. Migrated THP-1 cells were visualized under fluorescent microscope and quantified by counting three randomized 100 \times fields.

Co-culture of THP-1 and ovarian cancer cells was done in RPMI1640 + 10% FBS on 6-well cell culture inserts with 0.4 μm pore size, permeable PET membrane (BD Biosciences). Tumor cells were seeded at a density of 2×10^5 cells per insert in 1.5 mL medium. THP-1 cells were seeded at a density of 2×10^5 cells in the lower well in 3 mL medium. After co-culture for indicated periods, THP-1 cells were harvested for RNA extraction and subjected to qRT-PCR analysis.

In vivo xenograft studies

Five female SCID Hairless mice (aged 4-5 weeks, Charles River Laboratories) were randomly assigned to each experiment group. Xenografts were established in both subcutaneous (s.c.) and intraperitoneal (i.p.) models by injecting 5 million A224-derived cells or 2.5 million SKOV3-derived cells into the dorsal flank (s.c.) or abdominal right lower quadrant (i.p.) of the mouse. In the s.c. model, xenograft dimensions were measured by calipers twice a week and the tumor volume was calculated with the following formula: $V = 0.5 \times L \times W^2$ (L =larger diameter and W =smaller diameter). In the i.p. model, tumor burden was assessed by the total weight of the

xenografts after sacrifice. Mice were sacrificed 4 weeks (for FGF18 overexpression studies, due to the reach of ethical limit of tumor size) or 8 weeks (for FGF18 knockdown study, due to the low tumor growth rate) after tumor cell inoculation. All xenografts were fixed in 10% neutral buffered formalin, embedded in paraffin and cut consecutively into 4 μ m sections for further pathological examination (H&E staining) and IHC analysis.

Pharmacological treatment of PD173074 on in vivo xenografts

PD173074 treatment on tumor-bearing SCID mice was performed as previously described (2). Intraperitoneal xenografts were established by i.p. injection of 5 million FGF18 overexpressing A224 cells for 2.5 weeks. Mice were then randomly assigned to two groups for treatment and control (n=5 for each group). PD173074 was administrated intraperitoneally at a dosage of 25 mg/kg/day everyday for 7 days until the termination of the experiment. Solvent vehicle (20% DMSO in 1 \times PBS) at the same volume (0.4 mL) was employed as control. The tumor burden was assessed by the total tumor weight at the time of sacrifice.

Quantitative PCR analysis

Total RNA from cell culture was prepared by RNeasy mini kit (QIAGEN). Real-time quantitative PCR was performed on 50 ng of total RNA with SuperScript[®] III Platinum[®] One-Step qRT-PCR Kit (Invitrogen) in an iCycler iQ Real-Time PCR Detection System (Bio-Rad Laboratories). Relative expression of specific genes was calculated with the $2^{-\Delta\Delta CT}$ method. The expression levels of housekeeping genes GAPDH and PPIA (cyclophilin A) were used as internal controls in most of the cases except the THP-1 experiments, where ACTB (β -actin) was used instead of PPIA. The primer sequences are listed in Supplemental Table S5. Annealing temperature for all primer pairs was set at 59 °C.

Quantitative PCR for DNA copy number validation was performed on 10 ng of genomic DNA with iQ™ SYBR® Green Supermix (Bio-Rad). Three different primers sets were used for FGF18 and FGFR4. The paired primer sequences (F and R, 5' to 3') are listed as follows. FGF18 gDNA F1, CAGGGCGGGTAAAGCGACCDNA; FGF18 gDNA R1, CCTCACCTGCCACATCGC; FGF18 gDNA F2, CGCTGGTGAGTGAGTGCAG; FGF18 gDNA R2, CGATGCTCCCCAAGAACGCA; FGF18 gDNA F3, CTCCGCACTCCCTCGCCTAA; FGF18 gDNA R3, TTCACGGAGAGCGAGCGAAC; FGFR4 gDNA F1, CAGCAGGCAGAACCAAGTCTCC; FGFR4 gDNA R1, CCGCTGGAGGAGAGACGCA; FGFR4 gDNA F2, CAGGGTGCTTCTATGGGTGC; FGFR4 gDNA R2, GACGATGTGCTTCAGCCACT; FGFR4 gDNA F3, GGAAGGCAGTTGGTGGGAAG; FGFR4 gDNA R3, CTCTCCCACCTCAGAAGCCA; Line-1 F, AAAGCCGCTCAACTACATGG; Line-1 R, TGCTTTGAATGCGTCCCAGAG. Annealing temperature for all primer pairs was set at 59 °C. DNA content was normalized with the $2^{-\Delta\Delta CT}$ method to that of Line-1, a repetitive element for which copy numbers per haploid genome are similar among all normal and neoplastic cells (3). Relative DNA copy number was determined by normalizing to that of the average of three samples of normal human leukocyte DNA. Correlations between DNA copy numbers revealed from aCGH and qPCR were determined by Spearman's rho test.

Western blot analysis and immunoprecipitation

Total protein lysate was prepared from subconfluent cell culture by RIPA buffer with cocktail of protease and phosphatase inhibitors (Roche). For signal transduction analysis of pFRS2 and pErk1/2, subconfluent cells were first starved in RPMI + 0.1% FBS overnight before stimulation with 100 ng/mL rhFGF18 for 10 minutes. For compartmental protein extraction, cells

were lysed in a hypotonic buffer with 0.5% IGEPAL CA-630 and centrifuged to get the intact nucleus and the cytoplasmic fraction (supernatant). Nuclei were then lysed in RPIA buffer to get the nuclear fraction.

Protein concentration was estimated with BCA Protein Assay kit (Thermo Scientific). 20 µg of protein was separated by 4-15% SDS-PAGE (Bio-Rad) and transferred to nitrocellulose membrane (Amersham Biosciences). Antibody detection was performed with horseradish peroxidase (HRP) conjugated antibodies and SuperSignal Chemiluminescence Substrate system (Thermo Scientific).

Immunoprecipitation (IP) was performed with Pierce® Classic IP kit (Thermo Scientific). rhFGF18 stimulated cells were lysed in IP buffer containing 1% NP-40. Proteins with phosphorylated tyrosine were precipitated from 1 mg total protein by 3 µg phospho-tyrosine antibody (4G10, Millipore), captured by Protein A/G Plus agarose beads, and reconstituted through boiling in 60 µL Laemmli sample buffer. An aliquot of 15 µL was subjected to Western blot to detect tyrosine phosphorylated FGFR4, Erk1/2 and p38.

Expression profiling and microarray pathway analysis

Total genomic DNA free RNA was extracted by RNeasy Kit (QIAGEN) from three independent paired cultures of A224 cells overexpressing FGF18 or RFP. Synthesis of biotinylated cRNA was completed by one-round RNA amplification with GeneChip 3'-IVT Express Kit (Affymetrix) from 2.5 µg of total RNA. A 15 µg aliquot of cRNA was hybridized to an Affymetrix Human U133 Plus 2.0 GeneChip® array. Array data were collected with a laser confocal GeneChip® Scanner 3000 (Affymetrix).

JustRMA algorithm and median intensity of entire array were applied for data input and normalization by BRB ArrayTools version 4.1.0 (developed by Dr. Richard Simon et al, NCI,

NIH). Differentially regulated genes were identified by a univariate paired t-test ($p<0.0001$, fold-change >2.0 , random-variance model) from probe sets presenting in all arrays and displaying a variance in the top 50th percentile. Pathway enrichment analysis was performed by PathwayStudio 6.0 software (Ariadne Genomics). Potential FGF18-related pathways were identified by comparing the differential gene expression in response to ectopic FGF18 manipulation with a biological association network such as KEGG database (4).

References

1. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. *Nat Protoc.* 2010;5(4):628-635.
2. Crose LE et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. *Clin Cancer Res.* 2012;18(14):3780-3790.
3. Wang TL et al. Digital karyotyping. *Proc Natl Acad Sci U S A.* 2002;99(25):16156-16161.
4. Kanehisa M et al. KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Res.* 2012;40(Database issue):D109-D114.

SI Figures:




Figure S1. The expression level of FGF18 in different histological subtypes of epithelial ovarian cancer. (A) In dataset GSE6008 consisting of 41 serous, 13 mucinous, 37 endometrioid, 8 clear cell ovarian carcinomas and 4 individual normal ovary samples. **(B)** In dataset GSE29450 consisting of 10 clear cell ovarian carcinomas (CCOC) and 10 normal ovarian surface epithelium brushes (OSE). Array data import and normalization were performed by BRB array tools 4.1 with JustRMA algorism. Values on Y axis represent the cumulative intensity of all FGF18 probe sets. Mean±SEM is demonstrated for each group.

FGF18* *FGFR4




Figure S2. The detailed profile of the 7.3-Mb locus in chromosome 5 containing *FGF18* and *FGFR4* of the 2 representative tumors shown in Figure 1C (Upper panel: case 4595b; Lower panel: case 4963a). Copy number was presented by log₂ minus 1 (value of 0 mean diploid, 1 mean 4 copies, 2 mean 8 copies).




Figure S3. Kaplan-Meier analyses of the prognostic effects of debulking status, FIGO stage, tumor grade and the FGF18 IHC score on the 192 tumor samples from the validation tissue microarray. The cut-off of FGF18 IHC score was set at 6 (the highest score of FGF18 in benign ovarian cysts). Statistical significance was checked for each parameter. Detailed results were summarized in Table S1. Black lines: samples with optimal debulking / FIGO stage III / Grade 2 / Low FGF18; red broken lines: samples with suboptimal debulking / FIGO stage IV / Grade 3 / High FGF18; “+”: censored samples.




Figure S4. Multivariate Kaplan-Meier analysis of the prognostic effects of FGF18 expression level adjusted for the debulking status (A) or FIGO stage (B) on the 192 tumor samples from the validation tissue array. Statistical significance was checked for each parameter. The cut-off of FGF18 expression level was set at the IHC score of 6 (the highest score of FGF18 in benign ovarian cysts). Detailed results were summarized in Table S3. Black lines: samples with low FGF18; red broken lines: samples with high FGF18; “+”: censored samples.




Figure S5. Effect of FGF18 on the proliferation of OVCA429, A224 and SKOV3 cells. (A) and (B) Minimal effect of FGF18 overexpression on the proliferation of OVCA429 (A) and A224 (B) cells. Cells were cultured in 1% FBS to minimize the effect from serum. (C) Minimal effect of FGF18 knockdown on the proliferation of SKOV3 cells. Cell growth was assayed in both 1% FBS (left panel) and 10% FBS (right panel, to get exponent growth curves). Typical results were shown from three independent experiments.



A**B**

Figure S6. Stimulatory effect of FGF18 on HUVEC cells. (A) Stimulation of HUVEC tube formation by recombinant FGF18 (100 ng/mL), which can be ablated by the addition of 100 nM pan-FGFR inhibitor PD173074. Typical fluorescent microscopy images (bar: 500 µm) as well as the quantification were shown. **(B)** Conditioned medium from OVCA429 cells with ectopic FGF18 overexpression enhances HUVEC migration compared to conditioned medium from control RFP overexpressing cells. * p<0.05; mean±SD from three independent experiments.




Ki-67:**CD31:****F4/80:**

Figure S7. Immunohistochemical staining of the intraperitoneal xenografts derived from SKOV3 cells with FGF18 knockdown. Typical staining sections for human Ki-67, murine CD31 and murine F4/80 as well as the corresponding quantification are shown (bar: 100 μ m). Comparison was performed with the control SKOV3 with N/S shRNA (* p<0.05, ** p<0.001).



A**B**

Figure S8. qRT-PCR validation of expression changes in selected genes identified in the microarray analysis of A224 cells. Validation was performed in SKOV3 (A) and OVCA429 (B) cells with ectopic overexpression of FGF18 or RFP (as control). qRT-PCR was performed on three independent RNA samples. Significant changes ($p < 0.05$) were observed in all genes tested.





Figure S9. Activation of FRS2 and MAPK/Erk signaling by FGF18 which is susceptible to pan-FGFR inhibitor PD173074. The activation of FRS and Erk1/2 signals in A224 (**A**) and HUVEC (**B**) cells were detected by the increase of protein phosphorylation, as compared to untreated cells (FRS2 phosphorylation at Tyr-196, pErk1/2 phosphorylation at Thr202 and Tyr204). No effect on p38 activation was observed (detected by an antibody recognizing p38 only when phosphorylated at Thr180 and Tyr182). We therefore use the baseline p-p38 level as an internal control for the equal loading in Figure 6B.




Figure S10. Efficiency and specificity of siRNA mediated FGFR4 knockdown. FGFR4 siRNA at a dosage of 15 nM was transfected into A224 cells for 48 hours before harvest for qRT-PCR (left panel) and immunoblot (right panel). A scrambled, non-targeting (N/S) siRNA at same concentration was used as control.




Figure S11. M2 differentiation of THP-1 cells upon co-culture with RFP or FGF18-overexpressing SKOV3 cells. THP-1 cells were co-cultured with SKOV3 cells overexpressing RFP or FGF18 for 4 days before RNA harvest. With untreated THP-1 cells serving as control, quantitative RT-PCR was performed to quantify the expression of tumor-associated macrophage differentiation markers (IL-10 for oncogenic M2 differentiation, IL-12A for tumor-suppressive M1 differentiation) and other trophic / angiogenic factors (VEGF-A, CCL-2, IL-1, IL-8, CXCL-1 and MMP9). To compare the polarizing effects on THP-1 from the co-culture with RFP or FGF18-overexpressing SKOV3 cells, the relative fold-change for each gene tested and the related p-value (by paired t-test) were calculated and listed on the right.



A**B**

Figure S12. Insignificant effect of direct human recombinant FGF18 treatment on THP-1 cells. (A) THP-1 cells were starved in 0.5% FBS overnight before the treatment of rhFGF18, rhFGF1 or rhCCL2 at indicated concentrations for 10 minutes. FGF18 and FGF1 failed to induce phosphorylation of FRS2 and Erk1/2. In contrast, a significant activation of Erk1/2 was observed in response to CCL2. **(B)** Direct treatment of THP-1 cells with 100 ng/mL of rhFGF18 is insufficient for M2 polarization. Treatment was performed in RPMI + 2% FBS (to minimize the interference from growth factor in serum while keep the viability of THP-1 cells) for 4 days before RNA harvest for qRT-PCR analysis.




Figure S13. Susceptibility of FGF18 overexpression induced M2 polarization potential to pan-FGFR inhibitor PD173074. To make it comparable to Figure S11, co-culture of FGF18 or RFP overexpressing A224 cells and THP-1 cells was performed in RPMI + 2% FBS for 4 days before RNA harvest for qRT-PCR analysis. PD173074 (100 nM) or DMSO was added when co-culture was established until RNA harvest. Significant inhibitory effect of PD173074 on M2-polarizing potential ($p < 0.05$) were observed in every marker checked in FGF18 overexpressing A224 cells but not RFP overexpressing A224 cells.




Figure S14. Inhibitory effect of FGF18 knockdown on the M2 polarizing potential of SKOV3 cells. THP-1 cells were co-cultured with SKOV3 cells with FGF18 shRNA and non-targeting scrambled (N/S) shRNA 4 days before RNA harvest. With untreated THP-1 cells serving as control, qRT-PCR was performed to quantify the expression of tumor-associated macrophage differentiation markers. Significant changes ($p<0.05$) were observed in every marker checked for both FGF18 shRNA #1 and FGF18 shRNA #2 in comparison to the control N/S shRNA.

SI Tables

Table S1. Details of each univariate Kaplan-Meier curve analyzed. The information of sample description, estimated mean and median survival and comparative statistical tests were listed for **(A)** Mok et al (n=53); **(B)** Spentzos et al (n=70); **(C)** TAGA dataset (n=200); **(D)** FGF18 IHC staining of the tissue array (n=209); **(E)** The debulking status of the 192 tissue array samples (from the 209 samples on the same tissue array, for multivariate analysis); **(F)** The FIGO stage of the 192 tissue array samples; **(G)** The tumor grade of the 192 tissue array samples; and **(H)** The FGF18 expression level (IHC staining score) of the 192 tissue array samples.

(A) Mok et al (n=53)								
Case Processing Summary					Overall Comparisons			
FGF18	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
High	26	24	2	7.7%	Log Rank (Mantel-Cox)	13.606	1.000	0.00023
Low	27	17	10	37.0%	Breslow (Generalized Wilcoxon)	9.570	1.000	0.00198
Overall	53	41	12	22.6%	Tarone-Ware	11.262	1.000	0.00079
Means and Medians for Survival Time								
FGF18	Mean (Months)			Median (Months)				
	Estimate	Std. Error	95% Confidence Interval	Estimate		Std. Error	95% Confidence Interval	
High	24.493	3.716	17.209 - 31.777	18.000		2.335	13.424	22.576
Low	73.822	11.545	51.195 - 96.450	45.000		30.808	0.000	105.383
Overall	48.695	7.081	34.816 - 62.573	25.000		5.349	14.516	35.484
(B) Spentzos et al (n=70)								
Case Processing Summary					Overall Comparisons			
FGF18	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
High	35	15	20	57.1%	Log Rank (Mantel-Cox)	4.967	1.000	0.026
Low	35	25	10	28.6%	Breslow (Generalized Wilcoxon)	4.053	1.000	0.044
Overall	70	40	30	42.9%	Tarone-Ware	4.669	1.000	0.031
Means and Medians for Survival Time								
FGF18	Mean (Months)			Median (Months)				
	Estimate	Std. Error	95% Confidence Interval	Estimate		Std. Error	95% Confidence Interval	
High	65.802	8.958	48.244 - 83.361	54.000		8.567	37.209	70.791
Low	44.899	6.516	32.128 - 57.671	36.000		4.139	27.888	44.112
Overall	54.776	5.639	43.723 - 65.830	46.000		3.221	39.686	52.314
(C) TAGA dataset (n=200)								
Case Processing Summary					Overall Comparisons			
FGF18	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
High	100	55	45	45.0%	Log Rank (Mantel-Cox)	5.470	1.000	0.019
Low	100	45	55	55.0%	Breslow (Generalized Wilcoxon)	4.674	1.000	0.031
Overall	200	100	100	50.0%	Tarone-Ware	4.889	1.000	0.027
Means and Medians for Survival Time								
FGF18	Mean (Months)			Median (Months)				
	Estimate	Std. Error	95% Confidence Interval	Estimate		Std. Error	95% Confidence Interval	
High	45.378	3.135	39.233 - 51.522	45.600		5.279	35.252	55.948
Low	72.804	8.086	56.956 - 88.652	52.600		5.376	42.064	63.136
Overall	61.712	5.272	51.380 - 72.045	49.000		2.822	43.470	54.530
(D) FGF18 IHC staining of the tissue array (n=209)								
Case Processing Summary					Overall Comparisons			
FGF18	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
High	91	57	34	37.4%	Log Rank (Mantel-Cox)	9.824	1.000	0.00172
Low	118	75	43	36.4%	Breslow (Generalized Wilcoxon)	10.848	1.000	0.00099
Overall	209	132	77	36.8%	Tarone-Ware	10.703	1.000	0.00107
Means and Medians for Survival Time								
FGF18	Mean (Days)			Median (Days)				
	Estimate	Std. Error	95% Confidence Interval	Estimate		Std. Error	95% Confidence Interval	
High	1037.053	110.363	820.741 - 1253.366	898.000		96.484	708.891	1087.109
Low	1570.738	138.110	1300.042 - 1841.435	1126.000		71.124	986.598	1265.402
Overall	1351.230	95.153	1164.729 - 1537.730	1047.000		72.038	905.806	1188.194

(E) Debulking status of 192 tissue array samples								
Case Processing Summary					Overall Comparisons			
Debulk	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
optimal	141	91	50	35.5%	Log Rank (Mantel-Cox)	3.264	1.000	0.071
suboptimal	51	31	20	39.2%	Breslow (Generalized Wilcoxon)	6.201	1.000	0.013
Overall	192	122	70	36.5%	Tarone-Ware	4.716	1.000	0.030
Means and Medians for Survival Time								
Debulk	Mean (Days)				Median (Days)			
	Estimate	Std. Error	95% Confidence Interval		Estimate	Std. Error	95% Confidence Interval	
optimal	1463.980	123.518	1221.886	1706.074		1094.000	61.672	973.124 1214.876
suboptimal	1062.413	152.249	764.004	1360.821		870.000	162.775	550.962 1189.038
Overall	1364.482	102.464	1163.653	1565.311		1047.000	75.266	899.478 1194.522
(F) FIGO stage of 192 tissue array samples								
Case Processing Summary					Overall Comparisons			
FIGO Stage	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
III	149	96	53	35.6%	Log Rank (Mantel-Cox)	9.402	1.000	0.00217
IV	43	26	17	39.5%	Breslow (Generalized Wilcoxon)	9.708	1.000	0.00183
Overall	192	122	70	36.5%	Tarone-Ware	9.592	1.000	0.00195
Means and Medians for Survival Time								
FIGO Stage	Mean (Days)				Median (Days)			
	Estimate	Std. Error	95% Confidence Interval		Estimate	Std. Error	95% Confidence Interval	
III	1487.063	120.627	1250.635	1723.492		1094.000	78.639	939.867 1248.133
IV	863.510	116.587	635.000	1092.020		711.000	222.052	275.779 1146.221
Overall	1364.482	102.464	1163.653	1565.311		1047.000	75.266	899.478 1194.522
(G) Tumor grade of 192 tissue array samples								
Case Processing Summary					Overall Comparisons			
Grade	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
2	23	18	5	21.7%	Log Rank (Mantel-Cox)	.633	1.000	0.426
3	169	104	65	38.5%	Breslow (Generalized Wilcoxon)	.108	1.000	0.742
Overall	192	122	70	36.5%	Tarone-Ware	.360	1.000	0.549
Means and Medians for Survival Time								
Grade	Mean (Days)				Median (Days)			
	Estimate	Std. Error	95% Confidence Interval		Estimate	Std. Error	95% Confidence Interval	
2	1106.188	156.732	798.994	1413.382		999.000	79.190	843.787 1154.213
3	1396.051	113.004	1174.563	1617.539		1085.000	90.208	908.192 1261.808
Overall	1364.482	102.464	1163.653	1565.311		1047.000	75.266	899.478 1194.522
(H) FGF18 IHC staining of 192 tissue array samples								
Case Processing Summary					Overall Comparisons			
FGF18	Total N	N of Events	Censored			Chi-Square	df	Sig.
			N	Percent				
High	105	68	37	35.2%	Log Rank (Mantel-Cox)	12.926	1.000	0.00032
Low	87	54	33	37.9%	Breslow (Generalized Wilcoxon)	15.333	1.000	0.00009
Overall	192	122	70	36.5%	Tarone-Ware	14.833	1.000	0.00012
Means and Medians for Survival Time								
FGF18	Mean (Days)				Median (Days)			
	Estimate	Std. Error	95% Confidence Interval		Estimate	Std. Error	95% Confidence Interval	
High	1623.305	146.902	1335.377	1911.232		1129.000	80.301	971.610 1286.390
Low	969.027	99.467	774.072	1163.981		795.000	112.204	575.080 1014.920
Overall	1364.482	102.464	1163.653	1565.311		1047.000	75.266	899.478 1194.522

Table S2. Multivariate Cox regression analysis of the 192 samples on the validating tissue array. The prognostic impacts of FGF18 expression level (IHC score of 6 as cut-off), debulking status, FIGO stage and tumor grade on overall patient survival were indicated by the hazard ratio [Exp(B) in the table] and the corresponding p-value.

Categorical Variable		Frequency	(1)	
FGF18	High	87	1	
	Low	105	0	
Debulking	Suboptimal	51	1	
	Optimal	141	0	
FIGO Stage	IV	43	1	
	III	149	0	
Grade	3	169	1	
	2	23	0	
Variables in the Equation				
	p-value	Exp(B)	95.0% CI for Exp(B)	
			Lower	Upper
FGF18	0.00004	2.332	1.558	3.491
Debulking	0.48851	1.170	0.751	1.822
FIGO Stage	0.00103	2.202	1.374	3.529
Grade	0.03707	.560	0.324	0.966

Table S3. Details of the multivariate Kaplan-Meier analyses of the prognostic effects of FGF18 expression level adjusted for the debulking status (A) or FIGO stage (B) on the 192 tumor samples from the validation tissue array. The information of sample description, estimated mean and median survival and comparative statistical tests were listed.

(A) Adjusted for Debulking status										
Case Processing Summary						Overall Comparisons				
Debulk	FGF18	Total N	N of Events	Censored		Debulk	Chi-Square	Sig.		
				N	Percent					
Optimal	FGF18-	84	55	29	34.5%	Optimal	Log Rank	10.129	0.00146	
	FGF18+	57	36	21	36.8%		Wilcoxon	12.309	0.00045	
	Overall	141	91	50	35.5%		Tarone-Ware	11.683	0.00063	
Suboptimal	FGF18-	21	13	8	38.1%	Suboptimal	Log Rank	1.094	0.29563	
	FGF18+	30	18	12	40.0%		Wilcoxon	1.471	0.22521	
	Overall	51	31	20	39.2%		Tarone-Ware	1.429	0.23198	
Pooled		192	122	70	36.5%	Pooled	Log Rank	10.404	0.00126	
		Wilcoxon	13.665	0.00022						
		Tarone-Ware	13.097	0.00030						
Means and Medians for Survival Time										
Debulk	FGF18	Mean (Days)			Median (Days)					
		Estimate	Std. Error	95% Confidence		Estimate	Std. Error	95% Confidence		
				Lower Bound	Upper Bound			Lower Bound	Upper Bound	
Optimal	FGF18-	1702.1	166.4	1376.1	2028.2	1168.0		77.4	1016.3	1319.7
	FGF18+	992.2	112.9	771.0	1213.4	898.0		113.9	674.8	1121.2
	Overall	1464.0	123.5	1221.9	1706.1	1094.0		61.7	973.1	1214.9
Suboptimal	FGF18-	1229.5	239.3	760.5	1698.5	1085.0		278.4	539.4	1630.6
	FGF18+	928.5	197.2	542.0	1314.9	709.0		56.1	599.1	818.9
	Overall	1062.4	152.2	764.0	1360.8	870.0		162.8	551.0	1189.0
Overall		1364.5	102.5	1163.7	1565.3	1047.0		75.3	899.5	1194.5
(B) Adjusted for FIGO stage										
FIGO Stage	FGF18	Total N	N of Events	Censored		FIGO Stage		Chi-Square	Sig.	
				N	Percent					
III	FGF18-	82	54	28	34.1%	III	Log Rank	8.482	0.00359	
	FGF18+	67	42	25	37.3%		Wilcoxon	9.191	0.00243	
	Overall	149	96	53	35.6%		Tarone-Ware	8.956	0.00277	
IV	FGF18-	23	14	9	39.1%	IV	Log Rank	8.800	0.00301	
	FGF18+	20	12	8	40.0%		Wilcoxon	5.298	0.02135	
	Overall	43	26	17	39.5%		Tarone-Ware	6.827	0.00898	
Pooled		192	122	70	36.5%	Pooled	Log Rank	14.902	0.00011	
		Wilcoxon	11.338	0.00076						
		Tarone-Ware	12.793	0.00035						
Means and Medians for Survival Time										
FIGO Stage	FGF18	Mean (Days)			Median (Days)					
		Estimate	Std. Error	95% Confidence		Estimate	Std. Error	95% Confidence		
				Lower Bound	Upper Bound			Lower Bound	Upper Bound	
III	FGF18-	1751.9	173.6	1411.5	2092.2	1236.0		141.3	959.0	1513.0
	FGF18+	1077.0	115.1	851.4	1302.7	909.0		96.4	720.0	1098.0
	Overall	1487.1	120.6	1250.6	1723.5	1094.0		78.6	939.9	1248.1
IV	FGF18-	1110.4	163.0	790.9	1430.0	1085.0		25.3	1035.4	1134.6
	FGF18+	502.0	74.7	355.5	648.4	589.0		75.7	440.6	737.4
	Overall	863.5	116.6	635.0	1092.0	711.0		222.1	275.8	1146.2
Overall		1364.5	102.5	1163.7	1565.3	1047.0		75.3	899.5	1194.5

Table S4. Identification of FGF18–responsive genes by transcriptional profiling. Three paired RNA preparation of A224 cells overexpressing FGF18 or RFP (as control) were subjected to microarray analysis with Affymetrix Human U133 Plus 2.0 chips. Table sorted by fold-change between FGF18 and RFP-overexpressing A224 cells through paired comparison (class FGF18 and class RFP respectively). The first 704 probe sets are significant at the nominal 0.001 level of the univariate paired t-test.

Table S4:

Genes which are differentially expressed between FGF18 overexpressing A224 cells (class FGF18) and RFP overexpressing A224 cells (class RFP):

Number of genes significant at 0.001 level of the univariate test: 704
 Sorted by p-value of the univariate test.

Parametric p-value	FDR	Geometric mean of intensities (class FGF18 /class RFP)	Probe set	Gene symbol	Description	DefinedGenelist
1 < 1e-07	< 1e-07	93.95	<u>211485_s_at</u>	<u>FGF18</u>	fibroblast growth factor 18	membrane & extracellular protein, MAPK signaling pathway, Regulation of actin cytoskeleton
3 < 1e-07	< 1e-07	90.76	<u>206987_x_at</u>	<u>FGF18</u>	fibroblast growth factor 18	
2 < 1e-07	< 1e-07	79.38	<u>211029_x_at</u>	<u>FGF18</u>	fibroblast growth factor 18	
101 2.7E-06	2.8E-05	16.28	<u>205767_at</u>	<u>EREG</u>	epiregulin	membrane & extracellular protein
35 6.0E-07	1.7E-05	12.41	<u>201324_at</u>	<u>EMP1</u>	epithelial membrane protein 1	membrane & extracellular protein, tsnc

					membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, Acute Myocardial Infarction, Fibrinolysis Pathway, Platelet Amyloid Precursor Protein Pathway, Complement and coagulation cascades, immunology
4	< 1e-07	< 1e-07	11.45	<u>201860</u> s at <u>PLAT</u>	plasminogen activator, tissue
9	< 1e-07	< 1e-07	9.98	<u>203889</u> at <u>SCG5</u>	secretogranin V (7B2 protein)
119	3.3E-06	2.9E-05	8.68	<u>223484</u> at <u>C15orf48</u>	chromosome 15 open reading frame 48
65	1.4E-06	2.1E-05	7.95	<u>205239</u> at <u>AREG</u>	amphiregulin
164	5.6E-06	3.6E-05	7.73	<u>211506</u> s at <u>IL8</u>	interleukin 8

					receptor interaction, Epithelial cell signaling in Helicobacter pylori infection, Leukocyte transendothelial migration, Toll-like receptor signaling pathway, immunology
6	< 1e-07	7.49	<u>206074</u> s at	<u>HMGA1</u>	high mobility group AT-hook 1 Nuclear protein
43	8.0E-07	1.9E-05	7.26	<u>215856</u> at	<u>SIGLEC</u> <u>1.5</u> sialic acid binding Ig-like lectin 15 membrane & extracellular protein
168	5.9E-06	3.7E-05	7.17	<u>222934</u> s at	<u>CLEC4E</u> C-type lectin domain family 4, member E
443	1.1E-04	2.5E-04	7.01	<u>232504</u> at	<u>LOC285</u> <u>628</u> hypothetical protein LOC285628
170	5.9E-06	3.7E-05	7	<u>208025</u> s at	<u>HMGA2</u> high mobility group AT-hook 2 Nuclear protein
21	2.0E-07	8.8E-06	6.98	<u>203939</u> at	<u>NTSE</u> 5'-nucleotidase, ecto (CD73) membrane & extracellular protein, Nicotinate and nicotinamide metabolism, Purine metabolism, Pyrimidine metabolism

					membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, Cytokine-cytokine receptor interaction, Epithelial cell signaling in Helicobacter pylori infection
166	5.7E-06	3.6E-05	6.4	<u>204470</u> at <u>CXCL1</u>	chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
45	9.0E-07	1.9E-05	6.3	<u>205952</u> at <u>KCNK3</u>	potassium channel, subfamily K, member 3
36	6.0E-07	1.7E-05	6.14	<u>205207</u> at <u>IL6</u>	membrane & extracellular protein Cells and Molecules involved in local acute inflammatory response,
277	2.4E-05	9.1E-05	5.91	<u>202859</u> x at <u>IL8</u>	Cytokine Network, Cytokines and Inflammatory Response, Erythrocyte Differentiation Pathway, IL-17 Signaling Pathway, IL-5 Signaling Pathway, IL-6 signaling pathway, IL-10 Anti-inflammatory Signaling Pathway, Low-density lipoprotein (LDL) pathway during atherogenesis, Regulation of hematopoiesis by cytokines, Role of ERBB2 in Signal Transduction and Oncology, Signal transduction through IL1R, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Jak-STAT signaling pathway, Toll-like receptor signaling pathway, Immunology
					interleukin 6 (interferon, beta 2)
					interleukin 8

					membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, Cell Communication, ECM- receptor interaction, Focal adhesion
10	< 1e-07	< 1e-07	5.88	<u>201438</u> at <u>COL6A3</u>	collagen, type VI, alpha 3
312	3.2E-05	1.1E-04	5.37	<u>209774</u> X at <u>CXCL2</u>	chemokine (C-X-C motif) ligand 2
113	3.1E-06	2.9E-05	5.17	<u>210229</u> S at <u>CSE2</u>	colony stimulating factor 2 (granulocyte- macrophage)

					membrane & extracellular protein, Adhesion and Diapedesis of Granulocytes, Adhesion and Diapedesis of Lymphocytes, Cells and Molecules involved in local acute inflammatory response, Cytokine Network, Cytokines and Inflammatory Response, Erythrocyte Differentiation Pathway, IL-10 Anti- inflammatory Signaling Pathway, NF-kB Signaling Pathway, Signal transduction through IL1R, Stress Induction of HSP Regulation, Apoptosis, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, MAPK signaling pathway, Type I diabetes mellitus, immunology
358	4.4E-05	1.3E-04	5.13	<u>210118</u> s at <u>IL1A</u>	interleukin 1, alpha
210	1.1E-05	5.7E-05	4.94	<u>215101</u> s at <u>CXCL5</u>	chemokine (C-X-C motif) ligand 5
59	1.2E-06	2.1E-05	4.85	<u>201325</u> s at <u>EMP1</u>	epithelial membrane protein 1
85	1.8E-06	2.2E-05	4.49	<u>203037</u> s at <u>MTSS1</u>	metastasis suppressor 1
49	9.0E-07	1.9E-05	4.47	<u>227566</u> at <u>NTM</u>	neurotrimin

23	2.0E-07	8.8E-06	4.45	<u>1553995</u> a a t	<u>NTSE</u>	5'-nucleotidase, ecto (CD73)	membrane & extracellular protein, Nicotinate and nicotinamide metabolism, Purine metabolism, Pyrimidine metabolism	
24	2.0E-07	8.8E-06	4.44	<u>206157</u> at	<u>PTX3</u>	pentraxin-related gene, rapidly induced by IL-1 beta	membrane & extracellular protein, cell_cycle, cell_signaling, immunology	
336	3.8E-05	1.2E-04	4.28	<u>219859</u> at	<u>CLEC4E</u>	C-type lectin domain family 4, member E	membrane & extracellular protein	
397	6.5E-05	1.7E-04	4.16	<u>219764</u> at	<u>FZD10</u>	frizzled homolog 10 (Drosophila)	membrane & extracellular protein, Colorectal cancer, Wnt signaling pathway	
251	1.8E-05	7.4E-05	4.13	<u>219911</u> s at	<u>SLCO4A1</u>	solute carrier organic anion transporter family, member 4A1	membrane & extracellular protein	
204	1.1E-05	5.5E-05	4.1	<u>204726</u> at	<u>CDH13</u>	cadherin 13, H- cadherin (heart)	membrane & extracellular protein, cell_signaling, metastasis	
5	< 1e-07	< 1e-07	4.02	t	<u>1554624</u> a a	SIRPB1	signal-regulatory protein beta 1	membrane & extracellular protein
209	1.1E-05	5.7E-05	4.01	<u>210119</u> at	<u>KCNJ15</u>	potassium inwardly-rectifying channel, subfamily J, member 15	membrane & extracellular protein	
142	4.2E-06	3.1E-05	3.99	<u>242649</u> x at	<u>C15orf21</u>	Dresden prostate cancer 2	membrane & extracellular protein	

153	5.1E-06	3.5E-05	3.92	<u>205780</u> at <u>BIK</u>	BCL2-interacting killer (apoptosis-inducing)	membrane & extracellular protein, Role of Mitochondria in Apoptotic Signaling	
169	5.9E-06	3.7E-05	3.89	<u>239201</u> at <u>CDK15</u>	cyclin-dependent kinase 15		
93	2.3E-06	2.6E-05	3.84	<u>222878</u> s at <u>OTUB2</u>	OTU domain, ubiquitin aldehyde binding 2		
22	2.0E-07	8.8E-06	3.77	<u>206934</u> at <u>SIRPB1</u>	signal-regulatory protein beta 1	Biotin metabolism, Lysine degradation	
275	2.3E-05	9.0E-05	3.77	<u>218182</u> s at <u>CLDN1</u>	claudin 1	membrane & extracellular protein, Cell adhesion molecules (CAMS), Leukocyte transendothelial migration, Tight junction	
511	1.9E-04	4.0E-04	3.74	<u>225381</u> at <u>LOC399959</u>	hypothetical LOC399959		
77	1.6E-06	2.2E-05	3.69	<u>235146</u> at <u>TMCC3</u>	transmembrane and coiled-coil domain family 3	membrane & extracellular protein	
7	< 1e-07	< 1e-07	3.55	<u>204734</u> at <u>KRT15</u>	keratin 15	Cell Communication	
381	5.4E-05	1.5E-04	3.55	<u>214974</u> x at <u>CXCL5</u>	chemokine (C-X-C motif) ligand 5	membrane & extracellular protein, Cytokine-cytokine receptor interaction	
62	1.3E-06	2.1E-05	3.53	<u>201042</u> at <u>TGM2</u>	transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)	membrane & extracellular protein, Phospholipase C d1 in phospholipid associated cell signaling, Huntington's disease, immunology	

					membrane & extracellular protein, Cytokine-cytokine receptor interaction, TGF-beta signaling
308	3.1E-05	1.1E-04	3.53	<u>210511_s_at</u>	<u>INHBA</u> inhibin, beta A
309	3.2E-05	1.1E-04	3.52	<u>213711_at</u>	<u>KRT81</u> keratin 81
					membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes
383	5.7E-05	1.6E-04	3.48	<u>221019_s_at</u>	<u>COLEC1</u> collectin sub-family member 12
375	5.0E-05	1.4E-04	3.46	<u>202409_at</u>	<u>NA</u>
					membrane & extracellular protein, Nicotinate and nicotinamide metabolism, Purine metabolism, Pyrimidine metabolism
63	1.3E-06	2.1E-05	3.4	<u>227486_at</u>	<u>NT5E</u> 5'-nucleotidase, ecto (CD73)
					1-acylglycerol-3- phosphate O- acyltransferase 9
160	5.3E-06	3.5E-05	3.39	<u>224480_s_at</u>	<u>AGPAT9</u>
					membrane & extracellular protein
487	1.5E-04	3.3E-04	3.39	<u>210538_s_at</u>	<u>BIRC3</u> baculoviral IAP repeat-containing 3
					Nuclear protein, Caspase Cascade in Apoptosis, HIV-I Nef: negative effector of Fas and TNF, Induction of apoptosis through DR3 and DR4/5 Death Receptors , Role of Mitochondria in Apoptotic Signaling, SODD/TNFR1 Signaling Pathway, Apoptosis, Focal adhesion
70	1.5E-06	2.2E-05	3.37	<u>1553994_at</u>	<u>NT5E</u> 5'-nucleotidase, ecto (CD73)
					membrane & extracellular protein, Nicotinate and nicotinamide metabolism, Purine metabolism, Pyrimidine metabolism

Regulation of MAP Kinase Pathways							
Through Dual Specificity Phosphatases, MAPK signaling pathway							
190	8.3E-06	4.6E-05	3.37	<u>208892</u> s at	<u>DUSP6</u>	dual specificity phosphatase 6	
53	1.0E-06	2.0E-05	3.35	<u>219369</u> s at	<u>OTUB2</u>	OTU domain, ubiquitin aldehyde binding 2	Biotin metabolism, Lysine degradation
442	1.0E-04	2.5E-04	3.31	<u>222549</u> at	<u>CLDN1</u>	claudin 1	membrane & extracellular protein, Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, Tight junction
335	3.8E-05	1.2E-04	3.26	<u>204420</u> at	<u>FOSL1</u>	FOS-like antigen 1	membrane & extracellular protein, Nuclear protein, Bone Remodelling, Wnt signaling pathway, tsonc
11	< 1e-07	< 1e-07	3.23	<u>214702</u> at	<u>FN1</u>	fibronectin 1	membrane & extracellular protein, Cell Communication, ECM-receptor interaction, Focal adhesion, Regulation of actin cytoskeleton, angiogenesis, cell signaling, immunology, metastasis
83	1.8E-06	2.2E-05	3.23	<u>229461</u> x at	<u>NEGR1</u>	neuronal growth regulator 1	membrane & extracellular protein, Cell adhesion molecules (CAMs)
99	2.6E-06	2.8E-05	3.22	<u>221577</u> x at	<u>NA</u>	NA	membrane & extracellular protein
265	2.0E-05	8.1E-05	3.21	<u>225626</u> at	<u>PAG1</u>	phosphoprotein associated with glycosphingolipid microdomains 1	membrane & extracellular protein
148	4.6E-06	3.3E-05	3.17	<u>211343</u> s at	<u>COL13A1</u>	collagen, type XIII, alpha 1	membrane & extracellular protein

80	1.8E-06	2.2E-05	3.15	208607 s at	NA	NA	membrane & extracellular protein
635	5.5E-04	9.1E-04	3.14	<u>221911 at</u>	<u>ETV1</u>	ets variant 1	Nuclear protein, transcription, tsonc
50	9.0E-07	1.9E-05	3.11	<u>211003 x at</u>	<u>TGM2</u>	transglutaminase 2 (C polypeptide, protein-glutamine- gamma- glutamyltransferase)	membrane & extracellular protein, Phospholipase C d1 in phospholipid associated cell signaling, Huntington's disease, immunology
145	4.3E-06	3.1E-05	3.1	<u>211573 x at</u>	<u>TGM2</u>	transglutaminase 2 (C polypeptide, protein-glutamine- gamma- glutamyltransferase)	membrane & extracellular protein, Phospholipase C d1 in phospholipid associated cell signaling, Huntington's disease, immunology
69	1.4E-06	2.1E-05	3.07	<u>1552793 at</u>	<u>C8orf31</u>	chromosome 8 open reading frame 31	
38	7.0E-07	1.8E-05	3.04	<u>t</u>	<u>HMGA2</u>	high mobility group AT-hook 2	Nuclear protein
691	8.9E-04	1.4E-03	3.04	<u>207850 at</u>	<u>CXCL3</u>	chemokine (C-X-C motif) ligand 3	membrane & extracellular protein, Cytokine-cytokine receptor interaction
31	4.0E-07	1.4E-05	2.99	<u>209946 at</u>	<u>VEGFC</u>	vascular endothelial growth factor C	membrane & extracellular protein, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, angiogenesis
208	1.1E-05	5.7E-05	2.99	<u>225842 at</u>	<u>PHLDA1</u>	pleckstrin homology-like domain, family A,	membrane & extracellular protein, Nuclear protein

				member 1
385	5.8E-05	1.6E-04	2.94 <u>223782</u> s at	tubulointerstitial nephritis antigen membrane & extracellular protein
248	1.7E-05	7.2E-05	2.93 <u>231779</u> at	interleukin-1 receptor-associated kinase 2 Signal transduction through IL1R, Apoptosis, immunology, signal_transduction
278	2.4E-05	9.1E-05	2.93 <u>227354</u> at	phosphoprotein associated with glycosphingolipid microdomains 1 membrane & extracellular protein
74	1.6E-06	2.2E-05	2.92 <u>217999</u> s at	pleckstrin homology-like domain, family A, member 1 membrane & extracellular protein, Nuclear protein
52	1.0E-06	2.0E-05	2.86 <u>225166</u> at	Rho GTPase activating protein 18
17	2.0E-07	8.8E-06	2.83 <u>230494</u> at	solute carrier family 20 (phosphate transporter), member 1 membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer-Genes, immunology
304	3.0E-05	1.1E-04	2.83 <u>225622</u> at	phosphoprotein associated with glycosphingolipid microdomains 1 membrane & extracellular protein

				Nuclear protein, Arginine and proline metabolism, Ascorbate and aldarate metabolism, beta-Alanine metabolism, Bile acid biosynthesis, Butanoate metabolism, Fatty acid metabolism, Glycerolipid metabolism, Glycolysis / Gluconeogenesis, Histidine metabolism, Limonene and pinene degradation, Lysine degradation, Metabolism of xenobiotics by cytochrome P450, Phenylalanine metabolism, Propanoate metabolism, Pyruvate metabolism, Tryptophan metabolism, Tyrosine metabolism, Valine, leucine and isoleucine degradation
34	6.0E-07	1.7E-05	2.8	<u>203180</u> at <u>ALDH1</u> <u>A3</u>
250	1.7E-05	7.2E-05	2.74	<u>227478</u> at <u>SETBP1</u>
26	3.0E-07	1.1E-05	2.73	<u>211668</u> s at <u>PLAU</u>
293	2.7E-05	9.6E-05	2.72	<u>227342</u> s at <u>MYEOV</u>

								Perou's- Intrinsic- Breast-Cancer- Genes, Cell Communication
183	7.6E-06	4.4E-05	2.71	<u>209016 s at</u>	<u>KRT7</u>	keratin 7		
384	5.8E-05	1.6E-04	2.7	<u>211806 s at</u>	<u>KCNJ15</u>	potassium inwardly-rectifying channel, subfamily J, member 15	membrane & extracellular protein	
477	1.4E-04	3.1E-04	2.69	<u>223541 at</u>	<u>HAS3</u>	hyaluronan synthase 3	membrane & extracellular protein	
297	2.7E-05	9.6E-05	2.65	<u>203030 s at</u>	<u>PTPRN2</u>	protein tyrosine phosphatase, receptor type, N polypeptide 2	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, Type I diabetes mellitus, cell_cycle, cell_signaling	
674	7.8E-04	1.2E-03	2.63	<u>209277 at</u>	<u>TFPI2</u>	tissue factor pathway inhibitor 2	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, immunology	
41	7.0E-07	1.8E-05	2.61	<u>225847 at</u>	<u>NCEH1</u>	neutral cholesterol ester hydrolase 1	membrane & extracellular protein	
318	3.4E-05	1.1E-04	2.6	<u>201721 s at</u>	<u>LAPTM5</u>	lysosomal protein transmembrane 5	membrane & extracellular protein	
90	2.1E-06	2.5E-05	2.59	<u>205479 s at</u>	<u>PLAU</u>	plasminogen activator, urokinase	Fibrinolysis Pathway, Platelet Amyloid Precursor Protein Pathway, Complement and coagulation cascades, angiogenesis	
642	5.7E-04	9.3E-04	2.57	<u>209278 s at</u>	<u>TFPI2</u>	tissue factor pathway inhibitor 2	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, immunology	

641	5.6E-04	9.3E-04	2.51	<u>205552</u> s at <u>OAS1</u>	<u>2',5'-oligoadenylate synthetase 1, 40/46kDa</u>	Nuclear protein, cell_cycle, cell_signaling, immunology	
263	2.0E-05	7.9E-05	2.48	<u>217997</u> at <u>PHLDA1</u>	pleckstrin homology-like domain, family A, member 1	membrane & extracellular protein, Nuclear protein	
56	1.1E-06	2.1E-05	2.47	<u>205003</u> at <u>DOCK4</u>	dedicator of cytokinesis 4	membrane & extracellular protein	
404	7.1E-05	1.9E-04	2.47	<u>201720</u> s at <u>LAPTM5</u>	lysosomal protein transmembrane 5	membrane & extracellular protein	
558	2.8E-04	5.3E-04	2.47	<u>215189</u> at <u>KRT86</u>	keratin 86	Cell Communication	
276	2.4E-05	9.1E-05	2.46	<u>202267</u> at <u>LAMC2</u>	laminin, gamma 2	membrane & extracellular protein, Cell Communication, ECM-receptor interaction, Focal adhesion	
653	6.3E-04	1.0E-03	2.45	<u>214841</u> at <u>CNIH3</u>	cornichon homolog 3 (Drosophila)	membrane & extracellular protein	
29	3.0E-07	1.1E-05	2.42	<u>208891</u> at <u>DUSP6</u>	dual specificity phosphatase 6	Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases, MAPK signaling pathway	
413	7.8E-05	2.0E-04	2.41	<u>235318</u> at <u>FBN1</u>	fibrillin 1	membrane & extracellular protein, immunology	
227	1.4E-05	6.6E-05	2.39	<u>217998</u> at <u>NA</u>	NA	membrane & extracellular protein, Nuclear protein	

324	3.6E-05	1.2E-04	2.39	<u>203788</u> s at <u>SEMA3C</u>	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C	Nuclear protein, Perou's- Intrinsic-Breast-Cancer-Genes, BTG family proteins and cell cycle regulation, CARM1 and Regulation of the Estrogen Receptor, Cell Cycle: G1/S Check Point , Cyclins and Cell Cycle Regulation, Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages, Influence of Ras and Rho proteins on G1 to S Transition, p53 Signaling Pathway, WNT Signaling Pathway, Cell cycle, Colorectal cancer, Focal adhesion, Jak-STAT signaling pathway, Wnt signaling pathway, cell_cycle, tsong
544	2.5E-04	4.8E-04	2.39	<u>208712</u> at <u>CCND1</u>	cyclin D1	

					interaction, Focal adhesion
206	1.1E-05	5.6E-05	2.31	<u>201645</u> at <u>TNC</u>	membrane & extracellular protein, Nuclear protein, Perou's- Intrinsic-Breast-Cancer-Genes, Cell Communication, ECM-receptor interaction, Focal adhesion
120	3.3E-06	2.9E-05	2.3	<u>225566</u> at <u>NRP2</u>	neuropilin 2 angiogenesis
194	9.5E-06	5.1E-05	2.3	<u>203029</u> s at <u>PTPRN2</u>	protein tyrosine phosphatase, receptor type, N polypeptide 2 Perou's- Intrinsic- Breast-Cancer-Genes, Type I diabetes mellitus, cell_cycle, cell_signaling
290	2.6E-05	9.5E-05	2.3	<u>36711</u> at <u>MAFF</u>	v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) Nuclear protein, Oxidative Stress Induced Gene Expression Via Nrf2
180	6.9E-06	4.1E-05	2.29	<u>226489</u> at <u>TMCC3</u>	transmembrane and coiled-coil domain family 3 membrane & extracellular protein
205	1.1E-05	5.6E-05	2.29	<u>218000</u> s at <u>PHLDA1</u>	pleckstrin homology-like domain, family A, member 1 membrane & extracellular protein
579	3.3E-04	6.1E-04	2.29	<u>217388</u> s at <u>KYNU</u>	kynureinase (L-kynurenine hydrolase) Tryptophan metabolism

594	3.7E-04	6.6E-04	2.28	<u>205476</u> at	<u>CCL20</u>	chemokine (C-C motif) ligand 20	membrane & extracellular protein, Cytokine-cytokine receptor interaction
115	3.2E-06	2.9E-05	2.26	<u>202765</u> s at	<u>FBN1</u>	fibrillin 1	membrane & extracellular protein, immunology
273	2.3E-05	8.9E-05	2.26	<u>225173</u> at	<u>ARHGA</u> <u>P18</u>	Rho GTPase activating protein 18	membrane & extracellular protein, immunology
112	3.1E-06	2.9E-05	2.25	<u>202766</u> s at	<u>FBN1</u>	fibrillin 1	membrane & extracellular protein, immunology
260	1.9E-05	7.6E-05	2.25	<u>227529</u> s at	<u>AKAP12</u>	A kinase (PRKA) anchor protein 12	membrane & extracellular protein, Nuclear protein
211	1.2E-05	6.0E-05	2.23	<u>231154</u> x at	<u>TINAG</u>	tubulo-interstitial nephritis antigen	membrane & extracellular protein
464	1.2E-04	2.7E-04	2.22	<u>204011</u> at	<u>SPRY2</u>	sprouty homolog 2 (Drosophila)	membrane & extracellular protein, Sprouty regulation of tyrosine kinase signals, Jak-STAT signaling pathway
537	2.4E-04	4.6E-04	2.21	<u>230966</u> at	NA	NA	membrane & extracellular protein, Nuclear protein
71	1.5E-06	2.2E-05	2.19	<u>226028</u> at	<u>ROBO4</u>	roundabout homolog 4, magic roundabout (Drosophila)	membrane & extracellular protein
193	9.0E-06	4.9E-05	2.19	<u>214453</u> s at	<u>IFI44</u>	interferon-induced protein 44	membrane & extracellular protein
239	1.6E-05	7.0E-05	2.19	<u>206298</u> at	<u>ARHGA</u> <u>P22</u>	Rho GTPase activating protein 22	Nuclear protein

					membrane & extracellular protein, Lissencephaly gene (LIS1) in neuronal migration and development, Reelin Signaling Pathway, Cell Communication, ECM-receptor interaction, Focal adhesion
589	3.6E-04	6.4E-04	2.19	<u>205923</u> at <u>RELN</u>	reelin
692	9.0E-04	1.4E-03	2.19	<u>1553313</u> s a <u>t</u>	solute carrier family 5 (sodium/myo- inositol cotransporter), member 3
32	5.0E-07	1.7E-05	2.18	<u>210675</u> s at <u>PTPRR</u>	protein tyrosine phosphatase, receptor type, R
614	4.5E-04	7.8E-04	2.18	<u>219922</u> s at <u>LTPBP3</u>	latent transforming growth factor beta binding protein 3
175	6.5E-06	3.9E-05	2.17	<u>201830</u> s at <u>NET1</u>	neuroepithelial cell transforming 1
245	1.6E-05	7.1E-05	2.17	<u>237737</u> at <u>LOC100</u> <u>289026</u>	similar to hCG1744891
247	1.7E-05	7.1E-05	2.17	<u>203789</u> s at <u>SEMA3C</u>	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C
					membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes, Axon guidance

386	5.8E-05	1.6E-04	2.15	<u>213797</u> at	<u>RSAD2</u>	radical S-adenosyl methionine domain containing 2	membrane & extracellular protein
173	6.4E-06	3.9E-05	2.14	<u>210517</u> s at	<u>AKAP12</u>	A kinase (PRKA) anchor protein 12	membrane & extracellular protein, Nuclear protein
202	1.0E-05	5.4E-05	2.12	<u>203725</u> at	<u>GADD45</u> <u>Δ</u>	growth arrest and DNA-damage-inducible, alpha	Nuclear protein, ATM Signaling Pathway, Cell Cycle: G2/M Checkpoint, Hypoxia and p53 in the Cardiovascular system, p53 Signaling Pathway, Cell cycle, MAPK signaling pathway
518	2.0E-04	4.0E-04	2.12	<u>209199</u> s at	<u>MEF2C</u>	myocyte enhancer factor 2C	Nuclear protein, ALK in cardiac myocytes, CARM1 and Regulation of the Estrogen Receptor, NFAT and Hypertrophy of the heart (Transcription in the broken heart), MAPK signaling pathway
125	3.5E-06	2.9E-05	2.11	<u>229437</u> at	<u>MIR155</u> <u>HG</u>	MIR155 host gene (non-protein coding)	
334	3.8E-05	1.2E-04	2.11	<u>229225</u> at	<u>NRP2</u>	neuropilin 2	membrane & extracellular protein, angiogenesis
533	2.3E-04	4.6E-04	2.11	<u>230493</u> at	<u>SHISA2</u>	shisa homolog 2 (Xenopus laevis)	membrane & extracellular protein
151	4.8E-06	3.4E-05	2.1	<u>202566</u> s at	<u>SVIL</u>	supervillin	membrane & extracellular protein, Nuclear protein
149	4.8E-06	3.4E-05	2.08	<u>1567224</u> at	<u>HMGA2</u>	high mobility group AT-hook 2	Nuclear protein

186	8.1E-06	4.6E-05	2.08	<u>218986</u> s at <u>DDX60</u>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 60		
416	7.8E-05	2.0E-04	2.08	<u>210663</u> s at <u>KYNU</u>	kynureinase (L-kynurenine hydrolase)	Tryptophan metabolism	
89	2.1E-06	2.5E-05	2.07	<u>211844</u> s at <u>NRP2</u>	neuropilin 2	membrane & extracellular protein, angiogenesis	
133	3.8E-06	3.0E-05	2.07	<u>202565</u> s at <u>SVIL</u>	supervillin	membrane & extracellular protein, Nuclear protein	
323	3.6E-05	1.2E-04	2.07	<u>228033</u> at <u>E2F7</u>	E2F transcription factor 7	Nuclear protein	
359	4.4E-05	1.3E-04	2.07	<u>229610</u> at <u>CKAP2L</u>	cytoskeleton associated protein 2-like		
506	1.9E-04	3.9E-04	2.07	<u>218810</u> at <u>ZC3H12A</u>	zinc finger CCCH-type containing 12A	Nuclear protein	
574	3.2E-04	6.0E-04	2.07	<u>203439</u> s at <u>STC2</u>	stanniocalcin 2	membrane & extracellular protein	
576	3.3E-04	6.0E-04	2.07	<u>204439</u> at <u>IFI44L</u>	interferon-induced protein 44-like		
351	4.2E-05	1.3E-04	2.06	<u>224826</u> at <u>GPCPDL</u>	glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae)		
584	3.5E-04	6.3E-04	2.06	<u>219161</u> s at <u>CKLF</u>	chemokine-like factor	membrane & extracellular protein	

159	5.3E-06	3.5E-05	2.05	<u>204523</u> at	<u>ZNF140</u>	zinc finger protein 140	Nuclear protein, transcription
333	3.8E-05	1.2E-04	2.05	<u>206632</u> s at	<u>APOBEC</u> <u>3B</u>	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B	Atrazine degradation
361	4.5E-05	1.3E-04	2.05	<u>206376</u> at	<u>SLC6A1</u> 5	solute carrier family 6 (neutral amino acid transporter), member 15	membrane & extracellular protein
432	9.2E-05	2.2E-04	2.04	<u>204401</u> at	<u>KCNN4</u>	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	membrane & extracellular protein
271	2.2E-05	8.5E-05	2.02	<u>243409</u> at	<u>FOXL1</u>	forkhead box L1	
302	2.9E-05	1.0E-04	2.02	<u>222895</u> s at	<u>BCL11B</u>	B-cell CLL/lymphoma 11B (zinc finger protein)	
539	2.4E-04	4.7E-04	2.02	<u>219010</u> at	<u>C1orf106</u>	chromosome 1 open reading frame 106	
572	3.2E-04	6.0E-04	2.02	<u>1552546</u> a t	<u>LETM2</u>	leucine zipper-EF-hand containing transmembrane protein 2	membrane & extracellular protein

					membrane & extracellular protein, Dendritic cells in regulating TH1 and TH2 Development, SARS Coronavirus Protease, Glutathione metabolism, Hematopoietic cell lineage, angiogenesis, immunology, metastasis
106	2.9E-06	2.9E-05	2.01	<u>202888 s at ANPEP</u>	alanyl (membrane) aminopeptidase
217	1.3E-05	6.3E-05	2.01	<u>221530 s at BHLHE4_1</u>	basic helix-loop- helix family, member e41
226	1.4E-05	6.6E-05	2.01	<u>215177 s at ITGA6</u>	membrane & extracellular protein, Cell adhesion molecules (CAMs), Cell Communication, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Regulation of actin cytoskeleton, cell_signalling, immunology, metastasis
497	1.8E-04	3.8E-04	2.01	<u>218663 at NCAPG</u>	integrin, alpha 6 non-SMC condensin I complex, subunit G
631	5.3E-04	8.9E-04	2.01	<u>218400 at OAS3</u>	2'-5'-oligoadenylate synthetase 3, 100kDa
138	4.1E-06	3.1E-05	2	<u>219528 s at BCL11B</u>	B-cell CLL/lymphoma 11B (zinc finger protein)
					Nuclear protein

255	1.8E-05	7.4E-05	2	<u>223503</u> at <u>63</u>	transmembrane protein 163	membrane & extracellular protein	
564	2.9E-04	5.5E-04	2	<u>204729</u> s at <u>STX1A</u>	syntaxis 1A (brain)	membrane & extracellular protein, Blockade of Neurotransmitter Release by Botulinum Toxin	
285	2.6E-05	9.5E-05	1.99	<u>202862</u> at <u>EAH</u>	fumarylacetoacetate hydrolase (fumarylacetoacetas e)	Styrene degradation, Tyrosine metabolism, immunology	
352	4.2E-05	1.3E-04	1.99	<u>202644</u> s at <u>3</u>	tumor necrosis factor, alpha- induced protein 3	Nuclear protein, CD40L Signaling Pathway, NF-kB Signaling Pathway, TNFR2 Signaling Pathway	
436	9.9E-05	2.4E-04	1.99	<u>201829</u> at <u>NET1</u>	neuroepithelial cell transforming 1	Nuclear protein	
612	4.5E-04	7.8E-04	1.99	<u>208608</u> s at <u>SNTB1</u>	syntrophin, beta 1 (dystrophin- associated protein A1, 59kDa, basic component 1)	membrane & extracellular protein	
339	4.0E-05	1.2E-04	1.98	<u>216252</u> x at <u>FAS</u>		membrane & extracellular protein, Antigen Dependent B Cell Activation, Bystander B Cell Activation, CTL mediated immune response against target cells , FAS signaling pathway (CD95) , HIV Induced T Cell Apoptosis, HIV-I Nef: negative effector of Fas and TNF, IL-2 Receptor Beta Chain in T	

				cell Activation, Keratinocyte Differentiation, Regulation of transcriptional activity by PML, Stress Induction of HSP Regulation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus
409	7.3E-05	1.9E-04	1.97 <u>218943</u> s at <u>DDX58</u>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
560	2.8E-04	5.3E-04	1.97 <u>243357</u> at <u>NEGRI</u>	neuronal growth regulator 1
68	1.4E-06	2.1E-05	1.96 <u>222835</u> at <u>THSD4</u>	thrombospondin, type I, domain containing 4
689	8.6E-04	1.3E-03	1.96 <u>202869</u> at <u>OAS1</u>	2',5'-oligoadenylate synthetase 1, 40/46kDa
700	9.6E-04	1.5E-03	1.96 <u>213927</u> at <u>MAP3K9</u>	mitogen-activated protein kinase kinase kinase 9
369	4.7E-05	1.3E-04	1.95 <u>219209</u> at <u>IFIH1</u>	interferon induced with helicase C domain 1
435	9.7E-05	2.4E-04	1.95 <u>227530</u> at <u>AKAP12</u>	A kinase (PRKA) anchor protein 12

					GTPase, IMAP family member 2	membrane & extracellular protein
96	2.5E-06	2.7E-05	1.94	<u>232024</u> at <u>GIMAP2</u>	FXYD domain containing ion transport regulator 5	
354	4.3E-05	1.3E-04	1.94	<u>218084</u> x at <u>FXYD5</u>	chemokine-like factor	membrane & extracellular protein
580	3.4E-04	6.1E-04	1.94	<u>221058</u> s at <u>CKLF</u>	protein tyrosine phosphatase, receptor type, R	membrane & extracellular protein, Erk1/Erk2 Mapk Signaling pathway, MAPK signaling pathway
144	4.3E-06	3.1E-05	1.93	<u>206084</u> at <u>PTPRR</u>	melanophilin	
461	1.2E-04	2.7E-04	1.93	<u>218211</u> s at <u>MLPH</u>	nicotinamide phosphoribosyltran sferase	Nicotinate and nicotinamide metabolism
131	3.8E-06	3.0E-05	1.92	<u>243296</u> at <u>NAMPT</u>	FXYD domain containing ion transport regulator 5	membrane & extracellular protein, Antigen Dependent B Cell Activation, Bystander B Cell
326	3.6E-05	1.2E-04	1.92	<u>224252</u> s at <u>FXYD5</u>		Activation, CTL mediated immune response against target cells , FAS signaling pathway (CD95), HIV Induced T Cell Apoptosis, HIV-I Nef: negative effector of Fas and TNF, IL-2 Receptor Beta Chain in T cell Activation, Keratinocyte
509	1.9E-04	4.0E-04	1.92	<u>215719</u> x at <u>FAS</u>	Fas (TNF receptor superfamily, member 6)	

			Differentiation, Regulation of transcriptional activity by PML, Stress Induction of HSP Regulation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus
643	5.7E-04	9.4E-04	ubiquitin associated and SH3 domain containing, B <u>UBASH3</u> B
665	7.0E-04	1.1E-03	tubulin, gamma complex associated protein 2 <u>TUBGCP</u> 2
368	4.7E-05	1.3E-04	calcium channel, voltage-dependent, alpha 2/delta subunit 4 <u>CACNA</u> <u>2D4</u>
476	1.4E-04	3.1E-04	membrane & extracellular protein, MAPK signaling pathway pleckstrin homology-like domain, family A, member 1 <u>PHLDA1</u>

535	2.3E-04	4.6E-04	1.91	<u>201502 s at NFKB1A</u>	Nuclear protein, Acetylation and Deacetylation of RelA in The Nucleus, Activation of PKC through G protein coupled receptor, AKT Signaling Pathway, ATM Signaling Pathway, Cadmium induces DNA synthesis and proliferation in macrophages, CD40L Signaling Pathway, Chaperones modulate interferon Signaling Pathway, Double Stranded RNA Induced Gene Expression, Erythropoietin mediated neuroprotection through NF-kB, fMLP induced chemokine gene expression in HMC-1 cells, HIV-I Nef: negative effector of Fas and TNF, Induction of apoptosis through DR3 and DR4/5 Death Receptors , Influence of Ras and Rho proteins on G1 to S Transition, Keratinocyte Differentiation, MAPKinase Signaling Pathway, Mechanism of Gene Regulation by Peroxisome Proliferators via PPAR α (alpha), Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells, NFKB activation by Non-typeable Hemophilus influenzae, NF-kB Signaling Pathway, Signal

625	5.0E-04	8.5E-04	1.9	<u>218662</u> s at	<u>NCAPG</u>	non-SMC condensin I complex, subunit G	Nuclear protein
299	2.8E-05	9.9E-05	1.89	<u>233857</u> s at	<u>ASB2</u>	ankyrin repeat and SOCS box-containing 2	
365	4.6E-05	1.3E-04	1.89	<u>240572</u> s at	<u>LOC374</u> <u>443</u>	CLR pseudogene	
516	2.0E-04	4.0E-04	1.89	<u>226614</u> s at	<u>FAM167</u> <u>A</u>	family with sequence similarity 167, member A	
657	6.6E-04	1.1E-03	1.89	<u>213164</u> at	<u>NA</u>	NA	membrane & extracellular protein
556	2.8E-04	5.3E-04	1.88	<u>1558750</u> a a <u>t</u>	<u>LOC100</u> <u>288693</u>	hypothetical protein LOC100288693	
234	1.5E-05	6.7E-05	1.87	<u>205193</u> at	<u>MAFF</u>	v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)	Nuclear protein, Oxidative Stress Induced Gene Expression Via Nrf2
317	3.4E-05	1.1E-04	1.87	<u>227609</u> at	<u>EPSTI1</u>	epithelial stromal interaction 1 (breast)	
427	8.7E-05	2.1E-04	1.87	<u>210286</u> s at	<u>SLC4A7</u>	solute carrier family 4, sodium bicarbonate cotransporter, member 7	membrane & extracellular protein

534	2.3E-04	4.6E-04	1.86	<u>209270</u> at	<u>LAMB3</u>	laminin, beta 3		membrane & extracellular protein, Cell Communication, ECM-receptor interaction, Focal adhesion
626	5.1E-04	8.6E-04	1.86	<u>203349</u> s at	<u>ETV5</u>	ets variant 5		Nuclear protein, IL12 and Stat4 Dependent Signaling Pathway in Th1 Development, gene regulation, transcription
418	7.9E-05	2.0E-04	1.85	<u>217967</u> s at	<u>FAM129A</u>	family with sequence similarity 129, member A		
605	4.1E-04	7.2E-04	1.85	<u>223279</u> s at	<u>UACAA</u>	uveal autoantigen with coiled-coil domains and ankyrin repeats		membrane & extracellular protein, Nuclear protein
155	5.2E-06	3.5E-05	1.84	<u>203836</u> s at	<u>MAP3K5</u>	mitogen-activated protein kinase kinase kinase 5		membrane & extracellular protein, HIV-1 Nef: negative effector of Fas and TNF, Keratinocyte Differentiation, MAPKinase Signaling Pathway, p38 MAPK Signaling Pathway , The 4-1BB-dependent immune response, MAPK signaling pathway
268	2.1E-05	8.3E-05	1.84	<u>214456</u> x at	<u>NA</u>	NA		membrane & extracellular protein
345	4.1E-05	1.3E-04	1.84	<u>214012</u> at	<u>ERAP1</u>	endoplasmic reticulum aminopeptidase 1		
468	1.3E-04	2.9E-04	1.84	<u>217966</u> s at	<u>FAM129A</u>	family with sequence similarity 129, member A		

554	2.7E-04	5.2E-04	1.84	<u>214059</u> at	<u>IFI44</u>	interferon-induced protein 44	
651	6.1E-04	9.9E-04	1.84	<u>223451</u> s at	<u>CKLF</u>	chemokine-like factor	membrane & extracellular protein
195	9.5E-06	5.1E-05	1.83	<u>203837</u> at	<u>MAP3K5</u>	mitogen-activated protein kinase kinase kinase 5	membrane & extracellular protein, HIV-1 Nef, negative effector of Fas and TNF, Keratinocyte Differentiation, MAPKinase Signaling Pathway, p38 MAPK Signaling Pathway , The 4-1BB-dependent immune response, MAPK signaling pathway
422	8.1E-05	2.0E-04	1.83	<u>215726</u> s at	<u>CYB5A</u>	cytochrome b5 type A (microsomal)	membrane & extracellular protein, Peru's- Intrinsic- Breast-Cancer-Genes
640	5.6E-04	9.3E-04	1.83	<u>204014</u> at	<u>DUSP4</u>	dual specificity phosphatase 4	Nuclear protein, Peru's- Intrinsic-Breast-Cancer-Genes, Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases, MAPK signalling pathway, cell_cycle, cell_signaling
393	6.3E-05	1.7E-04	1.82	<u>236207</u> at	<u>SSFA2</u>	sperm specific antigen 2	membrane & extracellular protein
515	2.0E-04	4.0E-04	1.82	<u>212944</u> at	<u>SLC5A3</u>	solute carrier family 5 (sodium/myo-inositol cotransporter),	membrane & extracellular protein

					member 3	
703	9.8E-04	1.5E-03	1.82	<u>223513 at</u>	<u>CENPJ</u>	centromere protein J
230	1.4E-05	6.6E-05	1.81	<u>1554067 at</u>	<u>C12orf66</u>	chromosome 12 open reading frame 66
600	4.0E-04	7.1E-04	1.81	<u>204780 s at</u>	<u>FAS</u>	membrane & extracellular protein, Antigen Dependent B Cell Activation, Bystander B Cell Activation, CTL mediated immune response against target cells , FAS signaling pathway (CD95) , HIV Induced T Cell Apoptosis, HIV-I Nef: negative effector of Fas and TNF, IL-2 Receptor Beta Chain in T cell Activation, Keratinocyte Differentiation, Regulation of transcriptional activity by PML, Stress Induction of HSP Regulation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus

623	4.9E-04	8.3E-04	1.81	<u>226907</u> at <u>PPP1R14</u> <u>C</u>	protein phosphatase 1, regulatory (inhibitor) subunit 14C	membrane & extracellular protein	
329	3.7E-05	1.2E-04	1.8	<u>205659</u> at <u>HDAC9</u>	histone deacetylase 9	NA, Signal Dependent Regulation of Myogenesis by Corepressor MITR, Sumoylation by RanBP2 Regulates Transcriptional Repression	
171	6.0E-06	3.7E-05	1.79	<u>223423</u> at <u>GPR160</u>	G protein-coupled receptor 160	membrane & extracellular protein	
340	4.0E-05	1.2E-04	1.79	<u>211080</u> s at <u>NEK2</u>	NIMA (never in mitosis gene a)-related kinase 2	Nuclear protein	
652	6.2E-04	1.0E-03	1.79	<u>202481</u> at <u>DHRS3</u>	dehydrogenase/reductase (SDR family) member 3	membrane & extracellular protein, 1- and 2-Methylnaphthalene degradation, Benzoate degradation via CoA ligation, Bisphenol A degradation, Ethylbenzene degradation, gamma-Hexachlorocyclohexane degradation, Limonene and pinene degradation	
288	2.6E-05	9.5E-05	1.78	<u>231899</u> at <u>ZC3H12</u> <u>C</u>	zinc finger CCCH-type containing 12C	membrane & extracellular protein, Antigen processing and presentation, immunology	
347	4.1E-05	1.3E-04	1.78	<u>202902</u> s at <u>CTSS</u>	cathepsin S		

355	4.3E-05	1.3E-04	1.78	<u>207375 s at</u>	<u>IL15RA</u>	interleukin 15 receptor, alpha	membrane & extracellular protein, Nuclear protein, Cytokine-cytokine receptor interaction, Jak-STAT signalling pathway, immunology	
484	1.5E-04	3.2E-04	1.78	<u>211924 s at</u>	<u>PLAUR</u>	plasminogen activator, urokinase receptor	membrane & extracellular protein, Complement and coagulation cascades, angiogenesis	
172	6.3E-06	3.9E-05	1.77	<u>219073 s at</u>	<u>OSBPL1</u>	oxysterol binding protein-like 10	Nuclear protein	
650	6.0E-04	9.8E-04	1.77	<u>226438 at</u>	<u>SNTB1</u>	syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1)	membrane & extracellular protein	
469	1.3E-04	2.9E-04	1.76	<u>223381 at</u>	<u>NUF2</u>	NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae)	Nuclear protein	
242	1.6E-05	7.0E-05	1.75	<u>210845 s at</u>	<u>PLAUR</u>	plasminogen activator, urokinase receptor	membrane & extracellular protein, Complement and coagulation cascades, angiogenesis	
553	2.7E-04	5.1E-04	1.75	<u>224919 at</u>	<u>MRPS6</u>	mitochondrial ribosomal protein S6		
634	5.4E-04	8.9E-04	1.75	<u>204886 at</u>	<u>PLK4</u>	polo-like kinase 4 (Drosophila)		

201	1.0E-05	5.4E-05	1.74	<u>209200</u> at <u>MEF2C</u>	myocyte enhancer factor 2C	sperm specific antigen 2	Nuclear protein, ALK in cardiac myocytes, CARM1 and Regulation of the Estrogen Receptor, NFAT and Hypertrophy of the heart (Transcription in the broken heart), MAPK signaling pathway	
430	8.8E-05	2.2E-04	1.74	<u>202506</u> at <u>SSFA2</u>		NIMA (never in mitosis gene a)- related kinase 2	membrane & extracellular protein	
474	1.4E-04	3.1E-04	1.74	<u>204641</u> at <u>NEK2</u>		sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain,	Nuclear protein	
673	7.8E-04	1.2E-03	1.74	<u>234725</u> s at <u>SEMA4B</u>	(semaphorin) 4B	membrane & extracellular protein, Axon guidance		
444	1.1E-04	2.5E-04	1.73	<u>240407</u> at <u>LOC100126784</u>		hypothetical		
536	2.3E-04	4.6E-04	1.73	<u>223974</u> at <u>MGCI110</u>		hypothetical		
648	5.9E-04	9.6E-04	1.73	<u>220346</u> at <u>MTHFD2L</u>		methylenetetrahydr ofolate dehydrogenase (NADP+ dependent) 2-like		

677	7.9E-04	1.2E-03	1.73	<u>227198</u> at <u>AFF3</u>	AF4/FMR2 family, member 3	Nuclear protein	
					human immunodeficiency virus type I enhancer binding protein 3		
446	1.1E-04	2.5E-04	1.72	<u>235122</u> at <u>HIVEP3</u>		membrane & extracellular protein, Antigen Dependent B Cell Activation, Bystander B Cell Activation, CTL mediated immune response against target cells , FAS signaling pathway (CD95) , HIV Induced T Cell Apoptosis, HIV-I Nef: negative effector of Fas and TNF, IL-2 Receptor Beta Chain in T cell Activation, Keratinocyte Differentiation, Regulation of transcriptional activity by PML, Stress Induction of HSP Regulation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus	
488	1.5E-04	3.3E-04	1.72	<u>204781</u> s at <u>FAS</u>	Fas (TNF receptor superfamily, member 6)		
494	1.7E-04	3.6E-04	1.72	<u>235927</u> at <u>XPO1</u>	exportin 1 (CRM1 homolog, yeast)	Nuclear protein, Regulation of Spermatogenesis by CREM, Sonic Hedgehog (SHH) Receptor Ptcl Regulates cell cycle, gene _regulation, transcription	

658	6.6E-04	1.1E-03	1.72	<u>228359</u> at <u>B</u>	<u>UBASH3</u> <u>B</u>	ubiquitin associated and SH3 domain containing, B
663	7.0E-04	1.1E-03	1.72	<u>217010</u> s at <u>CDC25C</u>	cell division cycle 25 homolog C (S. pombe)	Nuclear protein, Activation of Src by Protein-tyrosine phosphatase alpha, cdc25 and chk1 Regulatory Pathway in response to DNA damage, Cell Cycle: G2/M Checkpoint, How Progesterone Initiates the Oocyte Maturation, RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage, Regulation of cell cycle progression by Plk3, Sonic Hedgehog (SHH) Receptor Ptcl Regulates cell cycle, Cell cycle, cell_cycle, cell_signaling
439	1.0E-04	2.4E-04	1.71	<u>203504</u> s at <u>ABCA1</u>	ATP-binding cassette, sub-family A (ABC1), member 1	membrane & extracellular protein, FXR and LXR Regulation of Cholesterol Metabolism, Nuclear Receptors in Lipid Metabolism and Toxicity
472	1.4E-04	3.0E-04	1.71	<u>223774</u> at <u>SNHG12</u>	small nucleolar RNA host gene 12 (non-protein coding)	polo-like kinase 4 (Drosophila)
696	9.4E-04	1.4E-03	1.71	<u>204887</u> s at <u>PLK4</u>		

				membrane & extracellular protein, Nuclear protein, Adipocytokine signaling pathway, Apoptosis, B cell receptor signaling pathway, Epithelial cell signalling in Helicobacter pylori infection, MAPK signaling pathway, T cell receptor signaling pathway, Toll-like receptor signaling pathway, gene regulation, immunology, transcription, tsonc
259	1.9E-05	7.6E-05	1.7	<u>207535</u> s at <u>NFKB2</u> nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
342	4.1E-05	1.3E-04	1.7	<u>213589</u> s at <u>B3GNTL</u> UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminylt ransferase-like 1
471	1.3E-04	3.0E-04	1.7	<u>225524</u> at <u>ANTXR2</u> anthrax toxin receptor 2
507	1.9E-04	3.9E-04	1.7	<u>209642</u> at <u>BUB1</u> budding uninhibited by benzimidazoles 1 homolog (yeast)
590	3.6E-04	6.5E-04	1.7	<u>205379</u> at <u>CBR3</u> carboxyl reductase 3
598	4.0E-04	7.0E-04	1.7	<u>239058</u> at <u>FOXC2</u> forkhead box C2 (MFH-1, mesenchyme forkhead 1)
267	2.1E-05	8.3E-05	1.69	<u>234023</u> s at <u>CENPJ</u> centromere protein J

563	2.9E-04	5.4E-04	1.69	<u>203234</u> at	<u>UPP1</u>	uridine phosphorylase 1 Pyrimidine metabolism	
					TAF4b RNA polymerase II, TATA box binding protein (TBP)-associated factor, 105kDa		
654	6.3E-04	1.0E-03	1.69	<u>235020</u> at	<u>TAF4B</u>	Basal transcription factors	
221	1.4E-05	6.5E-05	1.68	<u>205076</u> s at	<u>MTMR1</u>	myotubularin related protein 11	
					solute carrier family 20 (phosphate transporter), member 1	membrane & extracellular protein, Peru's- Intrinsic- Breast-Cancer- Genes, immunology	
223	1.4E-05	6.5E-05	1.68	<u>201920</u> at	<u>SLC20A1</u>	FYVE, RhoGEF and PH domain containing 6	
281	2.5E-05	9.4E-05	1.68	<u>1555137</u> a a	<u>FGD6</u>	XIAP associated	
316	3.3E-05	1.1E-04	1.67	<u>228617</u> at	<u>XAF1</u>	factor 1	
					chromosome 13 open reading frame 34	Nuclear protein	
699	9.6E-04	1.5E-03	1.67	<u>219544</u> at	<u>C13orf34</u>		
					hairy and enhancer of split 1, (Drosophila)	Nuclear protein, Segmentation Clock, Matuity onset diabetes of the young, Notch signaling pathway	
619	4.7E-04	8.0E-04	1.66	<u>203395</u> s at	<u>HES1</u>	interleukin 31 receptor A	membrane & extracellular protein
306	3.1E-05	1.1E-04	1.65	<u>243541</u> at	<u>IL3 IRA</u>		

414	7.8E-05	2.0E-04	1.65	<u>206364</u> at KIF14	kinesin family member 14	Nuclear protein	
					CD55 molecule, decay accelerating factor for complement (Cromer blood group)	membrane & extracellular protein, Complement and coagulation cascades, Hematopoietic cell lineage	
455	1.1E-04	2.6E-04	1.65	<u>201925</u> s at CD55	budding uninhibited by benzimidazoles 1 homolog (yeast)	Cell cycle, immunology	
541	2.4E-04	4.8E-04	1.65	<u>215509</u> s at BUB1	CKLF-like MARVEL transmembrane domain containing 1	CKLF-like MARVEL transmembrane domain containing 1	
668	7.3E-04	1.2E-03	1.65	<u>231219</u> at CMTM1	regulator of G-protein signaling 2, 24kDa	membrane & extracellular protein	
676	7.8E-04	1.2E-03	1.65	<u>202388</u> at RGS2	regulator of G-protein signaling 2, 24kDa	membrane & extracellular protein	
690	8.9E-04	1.4E-03	1.65	<u>205933</u> at SETBP1	SET binding protein 1	Nuclear protein	
597	3.9E-04	6.9E-04	1.64	<u>211519</u> s at KIF2C	kinesin family member 2C	Nuclear protein	
262	1.9E-05	7.7E-05	1.63	<u>202363</u> at SPOCK1	sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1	membrane & extracellular protein	

366	4.6E-04	1.3E-04	1.63	<u>226603</u> at <u>L</u>	<u>SAMD9</u> <u>L</u>	sterile alpha motif domain containing 9-like
447	1.1E-04	2.5E-04	1.62	<u>202863</u> at <u>SP100</u>	SP100 nuclear antigen	Nuclear protein, Regulation of transcriptional activity by PML, gene regulation, transcription
520	2.0E-04	4.1E-04	1.61	<u>212543</u> at <u>AIM1</u>	absent in melanoma 1	
636	5.5E-04	9.1E-04	1.61	<u>201802</u> at <u>1</u>	solute carrier family 29 (nucleoside transporters), member 1	
270	2.2E-05	8.5E-05	1.6	<u>224917</u> at <u>NA</u>	NA	membrane & extracellular protein
508	1.9E-04	4.0E-04	1.6	<u>205874</u> at <u>ITPKA</u>	inositol 1,4,5-trisphosphate 3-kinase A	membrane & extracellular protein
401	6.7E-05	1.8E-04	1.59	<u>205184</u> at <u>GNG4</u>	guanine nucleotide binding protein (G protein), gamma 4	Calcium signaling pathway, Inositol phosphate metabolism, Phosphatidylinositol signaling system
573	3.2E-04	6.0E-04	1.59	<u>232263</u> at <u>5</u>	solute carrier family 6 (neutral amino acid transporter), member 15	membrane & extracellular protein
617	4.7E-04	8.0E-04	1.59	<u>204492</u> at <u>ARHGA P11A</u>	Rho GTPase activating protein 11A	

659	6.8E-04	1.1E-03	1.59	<u>227080</u> at	<u>ZNF697</u>	zinc finger protein 697	Nuclear protein
420	7.9E-05	2.0E-04	1.56	<u>1569003</u> at	<u>TMEM49</u>	transmembrane protein 49	membrane & extracellular protein
524	2.1E-04	4.2E-04	1.56	<u>214179</u> s at	<u>NFE2L1</u>	nuclear factor (erythroid-derived 2)-like 1	Nuclear protein
394	6.4E-05	1.7E-04	1.55	<u>1555765</u> a a	<u>GNG4</u>	guanine nucleotide binding protein (G protein), gamma 4	membrane & extracellular protein
513	1.9E-04	4.0E-04	1.55	<u>237400</u> at	<u>ATP5S</u>	ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit s (factor B)	
529	2.2E-04	4.4E-04	1.55	<u>228323</u> at	<u>CASC5</u>	cancer susceptibility candidate 5	Nuclear protein
610	4.3E-04	7.5E-04	1.55	<u>223773</u> s at	<u>SNHG12</u>	small nucleolar RNA host gene 12 (non-protein coding)	
629	5.2E-04	8.7E-04	1.55	<u>219918</u> s at	<u>ASPM</u>	asp (abnormal spindle) homolog, microcephaly associated (Drosophila)	Nuclear protein

542	2.4E-04	4.8E-04	1.54	<u>242625</u> at	<u>RSAD2</u>	radical S-adenosyl methionine domain containing 2	membrane & extracellular protein
704	9.9E-04	1.5E-03	1.54	<u>201926</u> s at	<u>CD55</u>	CD55 molecule, decay accelerating factor for complement (Cromer blood group)	membrane & extracellular protein, Complement and coagulation cascades, Hematopoietic cell lineage
664	7.0E-04	1.1E-03	1.53	<u>202935</u> s at	<u>SOX9</u>	SRY (sex determining region Y)-box 9	Nuclear protein, development
679	7.9E-04	1.2E-03	1.53	<u>220241</u> at	<u>TMCO3</u>	transmembrane and coiled-coil domains 3	membrane & extracellular protein
445	1.1E-04	2.5E-04	1.52	<u>1557116</u> at	<u>APOL6</u>	apolipoprotein L, 6	membrane & extracellular protein
451	1.1E-04	2.6E-04	1.52	<u>202864</u> s at	<u>SP100</u>	SP100 nuclear antigen	Nuclear protein, Regulation of transcriptional activity by PML, gene regulation, transcription
662	7.0E-04	1.1E-03	1.52	<u>236957</u> at	<u>CDCA2</u>	cell division cycle associated 2	Nuclear protein
685	8.1E-04	1.2E-03	1.52	<u>230036</u> at	<u>SAMD9</u> <u>L</u>	sterile alpha motif domain containing 9-like	nuclear factor (erythroid-derived 2)-like 1
603	4.1E-04	7.2E-04	1.51	<u>200759</u> x at	<u>NFE2L1</u>		Nuclear protein

551	2.7E-04	5.1E-04	1.5	<u>213338</u> at <u>58</u>	transmembrane protein 158	membrane & extracellular protein
583	3.5E-04	6.3E-04	1.5	<u>216268</u> s at <u>JAG1</u>	jagged 1 (Alagille syndrome)	membrane & extracellular protein, Phosphoinositides and their downstream targets., Notch signalling pathway, angiogenesis, development, metastasis
501	1.8E-04	3.9E-04	1.49	<u>219863</u> at <u>HERC5</u>	hect domain and RLD 5	
568	3.0E-04	5.6E-04	1.49	<u>202411</u> at <u>IFI27</u>	interferon, alpha- inducible protein 27	membrane & extracellular protein
697	9.4E-04	1.4E-03	1.49	<u>200758</u> s at <u>NFE2L1</u>	nuclear factor (erythroid-derived 2)-like 1	Nuclear protein
504	1.9E-04	3.9E-04	1.47	<u>239697</u> x at <u>C3orf67</u>	chromosome 3 open reading frame 67	Nuclear protein
644	5.7E-04	9.4E-04	1.47	<u>213359</u> at <u>D</u> <u>HNRP</u>	heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa)	Nuclear protein
661	6.9E-04	1.1E-03	1.47	<u>1552619</u> a a <u>t</u> <u>ANLN</u>	anillin, actin binding protein	Nuclear protein
613	4.5E-04	7.8E-04	1.46	<u>205122</u> at <u>TMEFF1</u>	transmembrane protein with EGF- like and two	membrane & extracellular protein

				follistatin-like domains 1	
500	1.8E-04	3.9E-04	1.44 <u>226997</u> at <u>S12</u>	ADAM metallopeptidase with thrombospondin type 1 motif, 12	membrane & extracellular protein
596	3.8E-04	6.8E-04	1.44 <u>222608</u> s at <u>ANLN</u>	anillin, actin binding protein	Nuclear protein
682	8.0E-04	1.2E-03	1.44 <u>230097</u> at <u>GART</u>	phosphoribosylglyc inamide formyltransferase, phosphoribosylglyc inamide synthetase, phosphoribosylaminoimidazole synthetase	Nuclear protein, One carbon pool by folate, Purine metabolism, gene regulation, transcription
599	4.0E-04	7.0E-04	1.42 <u>204612</u> at <u>PKIA</u>	protein kinase (cAMP-dependent, catalytic) inhibitor alpha	Nuclear protein
557	2.8E-04	5.3E-04	1.41 <u>218543</u> s at <u>PARP12</u>	poly (ADP-ribose) polymerase family, member 12	Nuclear protein
602	4.1E-04	7.2E-04	1.37 <u>243999</u> at <u>SLFN5</u>	schlafin family member 5	Nuclear protein

637	5.5E-04	9.1E-04	1.36	<u>238430</u> x <u>at</u>	<u>SLFN5</u>	schlafen family member 5	Nuclear protein
694	9.1E-04	1.4E-03	1.32	<u>1557078</u> <u>at</u>	<u>SLFN5</u>	schlafen family member 5	Nuclear protein
681	8.0E-04	1.2E-03	0.71	<u>219225</u> <u>at</u>	<u>PGBD5</u>	piggyBac transposable element derived 5	membrane & extracellular protein
532	2.3E-04	4.6E-04	0.7	<u>219935</u> <u>at</u>	<u>ADAMT</u> <u>S5</u>	ADAM metallopeptidase with thrombospondin type 1 motif, 5	membrane & extracellular protein, Nuclear protein
546	2.5E-04	4.8E-04	0.69	<u>205306</u> x <u>at</u>	<u>KMO</u>	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	membrane & extracellular protein, Tryptophan metabolism
622	4.8E-04	8.2E-04	0.69	<u>215046</u> <u>at</u>	<u>C2orf67</u>	chromosome 2 open reading frame 67	
666	7.2E-04	1.1E-03	0.68	<u>208483</u> x <u>at</u>	<u>KRT33A</u>	keratin 33A	Cell Communication
698	9.5E-04	1.4E-03	0.67	<u>227481</u> <u>at</u>	<u>CNKSR3</u>	CNKSR family member 3	membrane & extracellular protein
423	8.2E-05	2.0E-04	0.66	<u>229357</u> <u>at</u>	<u>ADAMT</u> <u>S5</u>	ADAM metallopeptidase with thrombospondin type 1 motif, 5	membrane & extracellular protein, Nuclear protein

485	1.5E-04	3.2E-04	0.66	<u>227614</u> at <u>HKDC1</u>	hexokinase domain containing 1		
399	6.6E-05	1.7E-04	0.65	<u>201243</u> s at <u>ATP1B1</u>	ATPase, Na+/K+ transporting, beta 1 polypeptide	membrane & extracellular protein	
633	5.3E-04	8.9E-04	0.65	<u>210589</u> s at <u>GBAP1</u>	glucosidase, beta, acid pseudogene 1		
688	8.5E-04	1.3E-03	0.65	<u>209064</u> x at <u>PAIP1</u>	poly(A) binding protein interacting protein 1		
503	1.8E-04	3.9E-04	0.64	<u>212928</u> at <u>TSPY14</u>	TSPY-like 4	Nuclear protein	
586	3.5E-04	6.4E-04	0.64	<u>217908</u> s at <u>DCAF6</u>	DDB1 and CUL4 associated factor 6	Nuclear protein	
678	7.9E-04	1.2E-03	0.64	<u>229566</u> at <u>LOC645638</u>	WDN M1-like pseudogene		
702	9.7E-04	1.5E-03	0.64	<u>227919</u> at <u>UCA1</u>	urothelial cancer associated 1 (non-protein coding)		
402	6.9E-05	1.8E-04	0.63	<u>227556</u> at <u>NME7</u>	non-metastatic cells 7, protein expressed in (nucleoside-diphosphate kinase)	membrane & extracellular protein, Purine metabolism, Pyrimidine metabolism	
552	2.7E-04	5.1E-04	0.63	<u>229199</u> at <u>SCN9A</u>	sodium channel, voltage-gated, type IX, alpha subunit	membrane & extracellular protein	
611	4.4E-04	7.7E-04	0.63	<u>209087</u> x at <u>MCAM</u>	melanoma cell adhesion molecule	membrane & extracellular protein, Nuclear protein	

649	5.9E-04	9.6E-04	0.63	<u>231863</u> at <u>ING3</u>	inhibitor of growth family, member 3	Nuclear protein	
348	4.2E-05	1.3E-04	0.62	<u>235085</u> at <u>N</u>	homolog of rat pragma of Rnd2	membrane & extracellular protein	
417	7.8E-05	2.0E-04	0.62	<u>228948</u> at <u>EPHA4</u>	EPH receptor A4	membrane & extracellular protein, Eph Kinases and ephrins support platelet aggregation, Axon guidance, cell_cycle, cell_signaling, signal_transduction	
438	1.0E-04	2.4E-04	0.62	<u>211214</u> s at <u>DAPK1</u>	death-associated protein kinase 1	membrane & extracellular protein, cell_signalling, immunology	
456	1.1E-04	2.6E-04	0.62	<u>228494</u> at <u>PPP1R9A</u>	protein phosphatase 1, regulatory (inhibitor) subunit 9A		
491	1.6E-04	3.4E-04	0.62	<u>226360</u> at <u>ZNRF3</u>	zinc and ring finger 3	membrane & extracellular protein	
550	2.6E-04	4.9E-04	0.62	<u>209120</u> at <u>NR2F2</u>	nuclear receptor subfamily 2, group F, member 2	Nuclear protein	
349	4.2E-05	1.3E-04	0.61	<u>220244</u> at <u>LOH3CR2A</u>	loss of heterozygosity, 3, chromosomal region 2, gene A	reversion-inducing-cysteine-rich protein with kazal motifs	membrane & extracellular protein, Inhibition of Matrix Metalloproteinas
357	4.4E-05	1.3E-04	0.61	<u>205407</u> at <u>RECK</u>			

433	9.2E-05	2.2E-04	0.61	<u>210869</u> s at <u>MCAM</u>	melanoma cell adhesion molecule	membrane & extracellular protein, Nuclear protein	
527	2.2E-04	4.3E-04	0.61	<u>1561396</u> at <u>EPHA6</u>	EPH receptor A6	membrane & extracellular protein	
555	2.8E-04	5.3E-04	0.61	<u>202427</u> s at <u>BRP44</u>	brain protein 44		
559	2.8E-04	5.3E-04	0.61	<u>211555</u> s at <u>GUCY1B3</u>	guanylate cyclase 1, soluble, beta 3	Ion Channels and Their Functional Role in Vascular Endothelium, Gap junction, Long-term depression, Purine metabolism, signal_transduction	
570	3.2E-04	5.9E-04	0.61	<u>211237</u> s at <u>FGFR4</u>	fibroblast growth factor receptor 4	membrane & extracellular protein, Peru's- Intrinsic- Breast-Cancer- Genes, MAPK signaling pathway, Regulation of actin cytoskeleton, development, misc	
638	5.6E-04	9.2E-04	0.61	<u>233555</u> s at <u>SULF2</u>	sulfatase 2	membrane & extracellular protein	
645	5.8E-04	9.4E-04	0.61	<u>226776</u> at <u>ENY2</u>	enhancer of yellow 2 homolog (Drosophila)	Nuclear protein	
687	8.4E-04	1.3E-03	0.61	<u>203060</u> s at <u>PAPSS2</u>	3'- phosphoadenosine 5'-phosphosulfate synthase 2	Perou's- Intrinsic- Breast-Cancer- Genes, Purine metabolism, Selenoamino acid metabolism, Sulfur metabolism	
236	1.5E-05	6.8E-05	0.6	<u>207177</u> at <u>PTGFR</u>	prostaglandin F receptor (FP)	membrane & extracellular protein, Eicosanoid Metabolism, Calcium signaling pathway, Neuroactive ligand-receptor interaction	
241	1.6E-05	7.0E-05	0.6	<u>205347</u> s at <u>A</u>	thymosin beta 15a		

282	2.5E-05	9.4E-05	0.6	<u>227752</u> at <u>SPTLC3</u>	serine palmitoyltransferase, long chain base subunit 3	membrane & extracellular protein
291	2.6E-05	9.5E-05	0.6	<u>221942</u> s at <u>A3</u>	guanylate cyclase 1, soluble, alpha 3	Ion Channels and Their Functional Role in Vascular Endothelium, Gap junction, Long-term depression, Purine metabolism, immunology
356	4.4E-05	1.3E-04	0.6	<u>202796</u> at <u>SYNPO</u>	synaptopodin	membrane & extracellular protein
481	1.4E-04	3.2E-04	0.6	<u>202607</u> at <u>NDST1</u>	N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1	membrane & extracellular protein, Glycan structures - biosynthesis 1, Heparan sulfate biosynthesis
496	1.7E-04	3.7E-04	0.6	<u>233078</u> at <u>API5</u>	apoptosis inhibitor 5	Nuclear protein
530	2.2E-04	4.4E-04	0.6	<u>208134</u> x at <u>PSG2</u>	pregnancy specific beta-1-glycoprotein 2	membrane & extracellular protein
531	2.3E-04	4.5E-04	0.6	<u>203817</u> at <u>B3</u>	guanylate cyclase 1, soluble, beta 3	Ion Channels and Their Functional Role in Vascular Endothelium, Gap junction, Long-term depression, Purine metabolism, signal transduction
587	3.6E-04	6.4E-04	0.6	<u>209298</u> s at <u>ITSN1</u>	intersectin 1 (SH3 domain protein)	membrane & extracellular protein
200	1.0E-05	5.3E-05	0.59	<u>218031</u> s at <u>FOXN3</u>	forkhead box N3	Nuclear protein
218	1.3E-05	6.3E-05	0.59	<u>221886</u> at <u>2A</u>	DENN/MADD domain containing 2A	

370	4.7E-05	1.4E-04	0.59	<u>219093</u> at <u>PID1</u>	phosphotyrosine interaction domain containing 1	membrane & extracellular protein, Peru's- Intrinsic- Breast-Cancer- Genes, Neuroactive ligand-receptor interaction, immunology	
400	6.6E-05	1.8E-04	0.59	<u>205440</u> s at <u>NPY1R</u>	neuropeptide Y receptor Y1		
428	8.7E-05	2.1E-04	0.59	<u>244461</u> at <u>CYTSB</u>	cytospin B	Nuclear protein	
452	1.1E-04	2.6E-04	0.59	<u>233255</u> s at <u>BIVM</u>	basic, immunoglobulin-like variable motif containing		
482	1.4E-04	3.2E-04	0.59	<u>226775</u> at <u>ENY2</u>	enhancer of yellow 2 homolog (Drosophila)	Nuclear protein	
486	1.5E-04	3.2E-04	0.59	<u>224836</u> at <u>TP53INP2</u>	tumor protein p53 inducible nuclear protein 2	Nuclear protein	
					glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyl transferase)		
521	2.0E-04	4.1E-04	0.59	<u>239761</u> at <u>GCNT1</u>	collagen, type XII, alpha 1	membrane & extracellular protein, Glycan structures - biosynthesis 1, O-Glycan biosynthesis	
660	6.9E-04	1.1E-03	0.59	<u>231879</u> at <u>COL12A1</u>	ATPase, Na+/K+ transporting, beta 1	membrane & extracellular protein	
222	1.4E-05	6.5E-05	0.58	<u>201242</u> s at <u>ATP1B1</u>	polypeptide	membrane & extracellular protein	

305	3.1E-05	1.1E-04	0.58	<u>201818</u> at <u>LPCAT1</u>	lysophosphatidylcholine acyltransferase 1	membrane & extracellular protein	
322	3.6E-05	1.2E-04	0.58	<u>205670</u> at <u>GAL3ST1</u>	galactose-3-O-sulfotransferase 1	membrane & extracellular protein, Sphingolipid metabolism	
441	1.0E-04	2.5E-04	0.58	<u>209699</u> x at <u>AKR1C2</u>	aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type II)	Perou's- Intrinsic- Breast-Cancer-Genes, Metabolism of xenobiotics by cytochrome P450	
457	1.1E-04	2.6E-04	0.58	<u>226705</u> at <u>FGFR1</u>	fibroblast growth factor receptor 1	membrane & extracellular protein, Adherens junction, MAPK signaling pathway, Regulation of actin cytoskeleton, angiogenesis, cell_cycle, cell_signaling, development, immunology, misc, signal_transduction	
609	4.3E-04	7.5E-04	0.58	<u>204105</u> s at <u>NRCAM</u>	neuronal cell adhesion molecule	membrane & extracellular protein, Cell adhesion molecules (CAMs)	
670	7.5E-04	1.2E-03	0.58	<u>223079</u> s at <u>GLS</u>	glutaminase	D-Glutamine and D-glutamate metabolism, Glutamate metabolism, Nitrogen metabolism, immunology	
680	8.0E-04	1.2E-03	0.58	<u>226649</u> at <u>PANK1</u>	pantothenate kinase 1	Pantothenate and CoA biosynthesis	

253	1.8E-05	7.4E-05	0.57	<u>202555</u> s at	<u>MYLK</u>	myosin light chain kinase	Calcium signaling pathway, Focal adhesion, Regulation of actin cytoskeleton		
341	4.0E-05	1.2E-04	0.57	<u>226188</u> at	<u>HSPC15</u> <u>9</u>	galectin-related protein			
498	1.8E-04	3.8E-04	0.57	<u>219872</u> at	<u>FAM198</u> <u>B</u>	family with sequence similarity 198, member B	membrane & extracellular protein		
601	4.0E-04	7.1E-04	0.57	<u>218458</u> at	<u>GMCL1</u>	germ cell-less homolog 1 (Drosophila)	Nuclear protein		
165	5.7E-06	3.6E-05	0.56	<u>220441</u> at	<u>DNAJC2</u> <u>2</u>	Dnaj (Hsp40) homolog, subfamily C, member 22	membrane & extracellular protein		
320	3.5E-05	1.2E-04	0.56	<u>1555097</u> a a <u>t</u>	<u>PTGFR</u>	prostaglandin F receptor (FP)	Eicosanoid Metabolism, Calcium signaling pathway, Neuroactive ligand-receptor interaction		
434	9.5E-05	2.3E-04	0.56	<u>201487</u> at	<u>CTSC</u>	cathepsin C	immunology		
463	1.2E-04	2.7E-04	0.56	<u>227449</u> at	<u>EPHA4</u>	EPH receptor A4	membrane & extracellular protein, Eph Kinases and ephrins support platelet aggregation, Axon guidance, cell_cycle, cell_signaling, signal_transduction		
538	2.4E-04	4.7E-04	0.56	<u>230875</u> s at	<u>ATP11A</u>	ATPase, class VI, type 11A	membrane & extracellular protein		
621	4.8E-04	8.1E-04	0.56	<u>235228</u> at	<u>CCDC85</u> <u>A</u>	coiled-coil domain containing 85A			

684	8.1E-04	1.2E-03	0.56	234488 s at	NA	NA	Nuclear protein
215	1.3E-05	6.1E-05	0.55	221305 s at	NA	NA	membrane & extracellular protein
338	4.0E-05	1.2E-04	0.55	202237 at	NNMT	nicotinamide N-methyltransferase	Nicotinate and nicotinamide metabolism, immunology
449	1.1E-04	2.5E-04	0.55	208753 s at	NAP1L1	nucleosome assembly protein 1-like 1	Nuclear protein
450	1.1E-04	2.6E-04	0.55	225646 at	CTSC	cathepsin C	immunology
646	5.8E-04	9.4E-04	0.55	223721 s at	DNAJC1 2	Dnaj (Hsp40) homolog, subfamily C, member 12	
292	2.6E-05	9.6E-05	0.54	225136 at	PLEKHA 2	pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2	membrane & extracellular protein, Nuclear protein
392	6.3E-05	1.7E-04	0.54	206953 s at	LPHN2	latrophilin 2	membrane & extracellular protein
540	2.4E-04	4.7E-04	0.54	223827 at	TNFRSF 19	tumor necrosis factor receptor superfamily, member 19	membrane & extracellular protein, Cytokine-cytokine receptor interaction
549	2.5E-04	4.9E-04	0.54	206026 s at	TNFAIP 6	tumor necrosis factor, alpha-induced protein 6	immunology
595	3.8E-04	6.8E-04	0.54	239443 at	PCDHB6	protocadherin beta 6	membrane & extracellular protein

				<u>RUND</u>	<u>RUN domain containing 3B</u>	
620	4.7E-04	8.1E-04	0.54	<u>241703</u> at <u>3B</u>	Kallmann syndrome 1 sequence	membrane & extracellular protein, immunology
683	8.1E-04	1.2E-03	0.54	<u>205206</u> at <u>KAL1</u>		
102	2.7E-06	2.8E-05	0.53	<u>209772</u> s at <u>CD24</u>	CD24 molecule	membrane & extracellular protein
103	2.7E-06	2.8E-05	0.53	<u>210026</u> s at <u>CARD10</u>	caspase recruitment domain family, member 10	
141	4.1E-06	3.1E-05	0.53	<u>203399</u> x at <u>PSG3</u>	pregnancy specific beta-1-glycoprotein 3	membrane & extracellular protein
337	4.0E-05	1.2E-04	0.53	<u>213199</u> at <u>C2CD3</u>	C2 calcium-dependent domain containing 3	
371	4.7E-05	1.4E-04	0.53	<u>227812</u> at <u>TNFRSF19</u>	tumor necrosis factor receptor superfamily, member 19	membrane & extracellular protein, Cytokine-cytokine receptor interaction
374	4.9E-05	1.4E-04	0.53	<u>235343</u> at <u>VASH2</u>	vasohibin 2	
378	5.3E-05	1.5E-04	0.53	<u>230930</u> at <u>LOC338620</u>	hypothetical protein LOC338620	
389	6.0E-05	1.6E-04	0.53	<u>226794</u> at <u>STXBP5</u>	syntaxis binding protein 5 (tomasyn)	membrane & extracellular protein
458	1.1E-04	2.6E-04	0.53	<u>222714</u> s at <u>LACTB2</u>	lactamase, beta 2	
483	1.5E-04	3.2E-04	0.53	<u>243818</u> at <u>SFTA1P</u>	surfactant associated 1 (pseudogene)	

514	1.9E-04	4.0E-04	0.53	225647 s at	CTSC	cathepsin C	immunology
522	2.1E-04	4.2E-04	0.53	<u>209815</u> at	<u>PTCH1</u>	patched homolog 1 (Drosophila)	membrane & extracellular protein, Sonic Hedgehog (Shh) Pathway, Sonic Hedgehog (SHH) Receptor Ptcl Regulates cell cycle, Hedgehog signaling pathway
569	3.1E-04	5.8E-04	0.53	<u>227669</u> at	<u>BRP44</u>	brain protein 44	
571	3.2E-04	6.0E-04	0.53	<u>228397</u> at	<u>TUG1</u>	taurine upregulated 1 (non-protein coding)	
624	4.9E-04	8.3E-04	0.53	<u>206025</u> s at	<u>TNFAIP</u> <u>6</u>	tumor necrosis factor, alpha- induced protein 6	immunology
328	3.7E-05	1.2E-04	0.52	<u>242301</u> at	<u>CBLN2</u>	cerebellin 2 precursor	membrane & extracellular protein
462	1.2E-04	2.7E-04	0.52	<u>209377</u> s at	<u>HMGN3</u>	high mobility group nucleosomal binding domain 3	
467	1.3E-04	2.9E-04	0.52	<u>205795</u> at	<u>NRXN3</u>	neurexin 3	membrane & extracellular protein, Synaptic Proteins at the Synaptic Junction, Cell adhesion molecules (CAMs)
517	2.0E-04	4.0E-04	0.52	<u>225664</u> at	<u>COL12A</u> <u>1</u>	collagen, type XII, alpha 1	membrane & extracellular protein
229	1.4E-05	6.6E-05	0.51	<u>225602</u> at	<u>GLIPR2</u>	GLI pathogenesis- related 2	membrane & extracellular protein

266	2.1E-05	8.2E-05	0.51	<u>221697</u> at <u>2</u>	<u>MAP1LC</u> <u>3C</u>	microtubule-associated protein 1 light chain 3 gamma	membrane & extracellular protein
296	2.7E-05	9.6E-05	0.51	<u>231882</u> at <u>2</u>	<u>FLJ3963</u> <u>2</u>	hypothetical LOC642477	
332	3.7E-05	1.2E-04	0.51	<u>215821</u> X at <u>PSG3</u>	pregnancy specific beta-1-glycoprotein 3	membrane & extracellular protein	
346	4.1E-05	1.3E-04	0.51	<u>211828</u> s at <u>TNIK</u>	TRAF2 and NCK interacting kinase		
380	5.4E-05	1.5E-04	0.51	<u>225627</u> s at <u>1</u>	<u>CACHD</u> cache domain containing 1	membrane & extracellular protein	
403	6.9E-05	1.8E-04	0.51	<u>218261</u> at <u>AP1M2</u>	adaptor-related protein complex 1, mu 2 subunit	membrane & extracellular protein	
426	8.6E-05	2.1E-04	0.51	<u>201279</u> s at <u>DAB2</u>	disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)	membrane & extracellular protein	
431	9.0E-05	2.2E-04	0.51	<u>225241</u> at <u>CCDC80</u>	coiled-coil domain containing 80	membrane & extracellular protein	
489	1.6E-04	3.4E-04	0.51	<u>215321</u> at <u>3B</u>	<u>RUND</u> RUN domain containing 3B	D-Glutamine and D-glutamate metabolism, Glutamate metabolism, Nitrogen metabolism, immunology	
502	1.8E-04	3.9E-04	0.51	<u>203158</u> s at <u>GLS</u>	glutaminase		

100	2.6E-06	2.8E-05	0.5	<u>227550_at</u>	<u>GFRA1</u>	GDNF family receptor alpha 1	membrane & extracellular protein
105	2.8E-06	2.8E-05	0.5	<u>212093_s_at</u>	<u>MTUS1</u>	microtubule associated tumor suppressor 1	membrane & extracellular protein, Nuclear protein
156	5.2E-06	3.5E-05	0.5	<u>204984_at</u>	<u>GPC4</u>	glypican 4	membrane & extracellular protein
279	2.5E-05	9.3E-05	0.5	<u>213882_at</u>	<u>TM2D1</u>	TM2 domain containing 1	membrane & extracellular protein
421	8.0E-05	2.0E-04	0.5	<u>201309_x_at</u>	<u>C5orf13</u>	chromosome 5 open reading frame 13	membrane & extracellular protein
562	2.9E-04	5.4E-04	0.5	<u>213183_s_at</u>	<u>CDKN1C</u>	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	Nuclear protein, Cell cycle, cell_cycle, immunology, tsonc
567	3.0E-04	5.6E-04	0.5	<u>244183_x_at</u>	<u>PCDHB3</u>	protocadherin beta 3	membrane & extracellular protein
628	5.1E-04	8.6E-04	0.5	<u>231726_at</u>	<u>PCDHB1</u>	protocadherin beta 14	membrane & extracellular protein
55	1.1E-06	2.1E-05	0.49	<u>218574_s_at</u>	<u>LMCD1</u>	LIM and cysteine-rich domains 1	Nuclear protein
146	4.4E-06	3.2E-05	0.49	<u>213307_at</u>	<u>SHANK2</u>	SH3 and multiple ankyrin repeat domains 2	membrane & extracellular protein
197	9.7E-06	5.2E-05	0.49	<u>202017_at</u>	<u>EPHX1</u>	epoxide hydrolase 1, microsomal (xenobiotic)	Eicosanoid Metabolism, Metabolism of xenobiotics by cytochrome P450, immunology, metabolism, pharmacology

				membrane & extracellular protein, Hypoxia-Inducible Factor in the Cardiovascular System, NFAT and Hypertrophy of the heart (Transcription in the broken heart), Role of EGF Receptor
				Transactivation by GPCRs in Cardiac Hypertrophy, Neuroactive ligand- receptor interaction, development, immunology, misc
228	1.4E-05	6.6E-05	0.49	<u>218995</u> s at <u>EDN1</u> endothelin 1
238	1.6E-05	6.9E-05	0.49	<u>236344</u> at <u>PDE1C</u> phosphodiesterase 1C, calmodulin- dependent 70kDa
261	1.9E-05	7.6E-05	0.49	<u>242546</u> at <u>FLJ3963</u> <u>2</u> hypothetical LOC642477
364	4.6E-05	1.3E-04	0.49	<u>206363</u> at <u>MAF</u> v-maf musculoaponeuroti c fibrosarcoma oncogene homolog (avian)
390	6.0E-05	1.6E-04	0.49	<u>201301</u> s at <u>ANXA4</u> annexin A4
466	1.3E-04	2.9E-04	0.49	<u>209426</u> s at <u>AMACR</u> alpha-methylacyl- CoA racemase
505	1.9E-04	3.9E-04	0.49	<u>204720</u> s at <u>DNAJC6</u> DnaJ (Hsp40) homolog, subfamily C, member 6
591	3.7E-04	6.5E-04	0.49	<u>218976</u> at <u>DNAJC1</u> <u>2</u> DnaJ (Hsp40) homolog, subfamily C, member 12

				v-maf musculoaponeuroti c fibrosarcoma oncogene homolog (avian)	Nuclear protein, tsonc
630	5.2E-04	8.8E-04	0.49	<u>229327</u> s at <u>MAF</u>	
655	6.4E-04	1.0E-03	0.49	<u>1554966</u> a a <u>t</u> <u>FILIP1L</u>	filamin A interacting protein 1-like
671	7.6E-04	1.2E-03	0.49	<u>229800</u> at <u>DCLK1</u>	doublecortin-like kinase 1
54	1.0E-06	2.0E-05	0.48	<u>228754</u> at <u>SLC6A6</u>	solute carrier family 6 (neurotransmitter transporter, taurine), member 6
81	1.8E-06	2.2E-05	0.48	<u>218660</u> at <u>DYSF</u>	dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive)
269	2.1E-05	8.3E-05	0.48	<u>B4GALT</u> <u>1</u> <u>1</u> <u>1</u>	UDP- Gal:betaGlcNAc beta 1,4- galactosyltransferas e, polypeptide 1

300	2.8E-05	9.9E-05	0.48	<u>227404</u> s at <u>EGR1</u>	early growth response 1	Nuclear protein, Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway, cell_cycle, cell_signaling, gene_regulation, immunology, transcription	membrane & extracellular protein, Nuclear protein, Acute Myocardial Infarction, Extrinsic Prothrombin Activation Pathway, Intrinsic Prothrombin Activation Pathway, Complement and coagulation cascades, immunology	
313	3.3E-05	1.1E-04	0.48	<u>207808</u> s at <u>PROS1</u>	protein S (alpha)	disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)	membrane & extracellular protein	
398	6.5E-05	1.7E-04	0.48	<u>201280</u> s at <u>DAB2</u>	MCC	mutated in colorectal cancers	immunology, tsnc	
425	8.5E-05	2.1E-04	0.48	<u>226225</u> at <u>PCDHBL1</u>	protocadherin beta 10	protocadherin beta 10	membrane & extracellular protein	
437	9.9E-05	2.4E-04	0.48	<u>223854</u> at <u>0</u>			membrane & extracellular protein	
547	2.5E-04	4.8E-04	0.48	<u>221207</u> s at <u>NBEA</u>	neurobeachin	neurobeachin	membrane & extracellular protein	
627	5.1E-04	8.6E-04	0.48	<u>243864</u> at <u>CCDC80</u>	coiled-coil domain containing 80	coiled-coil domain containing 80	membrane & extracellular protein	
57	1.2E-06	2.1E-05	0.47	<u>226071</u> at <u>ADAMT</u>	<u>SL4</u>	ADAMTS-like 4	membrane & extracellular protein	
104	2.8E-06	2.8E-05	0.47	<u>219304</u> s at <u>PDGFDF</u>	platelet derived growth factor D	platelet derived growth factor D	membrane & extracellular protein, Focal adhesion, Gap junction	

108	3.0E-06	2.9E-05	0.47	209994 s at	NA	NA		membrane & extracellular protein	
158	5.3E-06	3.5E-05	0.47	<u>206517</u> at	<u>CDH16</u>	cadherin 16, KSP-cadherin		membrane & extracellular protein	
295	2.7E-05	9.6E-05	0.47	229978 at	<u>SHISA9</u>	shisa homolog 9 (Xenopus laevis)			
419	7.9E-05	2.0E-04	0.47	<u>226439</u> s at	<u>NBEA</u>	neurobeachin		membrane & extracellular protein	
578	3.3E-04	6.0E-04	0.47	<u>221747</u> at	<u>TNS1</u>	tensin 1		Integrin Signaling Pathway	
695	9.3E-04	1.4E-03	0.47	<u>218162</u> at	<u>OLFML3</u>	olfactomedin-like 3		membrane & extracellular protein	
67	1.4E-06	2.1E-05	0.46	<u>213974</u> at	<u>ADAMT</u>	ADAMTS-like 3		membrane & extracellular protein	
127	3.6E-06	3.0E-05	0.46	<u>225817</u> at	<u>CGNL1</u>	cingulin-like 1 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9		Cysteine metabolism	
128	3.6E-06	3.0E-05	0.46	<u>223737</u> x at	<u>CHST9</u>	BTG family, member 3		Perou's- Intrinsic- Breast-Cancer-Genes	
136	4.0E-06	3.1E-05	0.46	<u>215425</u> at	<u>BTG3</u>	heat shock transcription factor 2 binding protein			
212	1.2E-05	6.1E-05	0.46	<u>207020</u> at	<u>HSF2BP</u>				
289	2.6E-05	9.5E-05	0.46	<u>225968</u> at	<u>PRICKL</u> <u>E2</u>	prickle homolog 2 (Drosophila)		Nuclear protein, Wnt signaling pathway	
314	3.3E-05	1.1E-04	0.46	<u>204579</u> at	<u>FGFR4</u>	fibroblast growth factor receptor 4		membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer-Genes, MAPK signaling pathway, Regulation of actin cytoskeleton, development, misc	

395	6.4E-05	1.7E-04	0.46	<u>201278</u> at DAB2	disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)	membrane & extracellular protein	
616	4.6E-04	7.9E-04	0.46	<u>202746</u> at ITM2A	integral membrane protein 2A	membrane & extracellular protein	
33	6.0E-07	1.7E-05	0.45	<u>203126</u> at IMPA2	inositol(myo)-1(or 4)-monophosphatase 2	Inositol phosphate metabolism, Phosphatidylinositol signaling system, Streptomycin biosynthesis	
46	9.0E-07	1.9E-05	0.45	<u>213171</u> s at MMP24	matrix metallopeptidase 24 (membrane-inserted)	membrane & extracellular protein	
51	9.0E-07	1.9E-05	0.45	<u>209993</u> at ABCB1	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Hypoxia and p53 in the Cardiovascular system, Multi-Drug Resistance Factors, Nuclear Receptors in Lipid Metabolism and Toxicity	
214	1.2E-05	6.1E-05	0.45	<u>225604</u> s at GLIPR2	GLI pathogenesis-related 2	membrane & extracellular protein	
232	1.4E-05	6.6E-05	0.45	<u>223449</u> at SEMA6A	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A	membrane & extracellular protein, Axon guidance	

					membrane & extracellular protein, Hypoxia-Inducible Factor in the Cardiovascular System, NFAT and Hypertrophy of the heart (Transcription in the broken heart), Role of EGF Receptor
					Transactivation by GPCRs in Cardiac Hypertrophy, Neuroactive ligand- receptor interaction, development, immunology, misc
235	1.5E-05	6.7E-05	0.45	<u>222802_at</u>	<u>EDN1</u> endothelin 1
237	1.5E-05	6.9E-05	0.45	<u>218807_at</u>	<u>VAV3</u> vav 3 guanine nucleotide exchange factor
479	1.4E-04	3.1E-04	0.45	<u>219619_at</u>	<u>DIRAS2</u> DIRAS family, GTP-binding RAS- like 2
543	2.4E-04	4.8E-04	0.45	<u>212192_at</u>	<u>KCTD12</u> potassium channel tetramerisation domain containing 12
582	3.5E-04	6.3E-04	0.45	<u>209425_at</u>	<u>AMACR</u> alpha-methylacyl- CoA racemase
60	1.2E-06	2.1E-05	0.44	<u>239093_at</u>	<u>DHDPSL</u> dihydrodipicolinate synthase-like, mitochondrial

139	4.1E-06	3.1E-05	0.44	<u>213227</u> at <u>2</u>	<u>PGRMC</u> <u>2</u>	progesterone receptor membrane component 2	membrane & extracellular protein
143	4.2E-06	3.1E-05	0.44	<u>203157</u> s at <u>GLS</u>	glutaminase	D-Glutamine and D-glutamate metabolism, Glutamate metabolism, Nitrogen metabolism, immunology	
213	1.2E-05	6.1E-05	0.44	<u>217677</u> at <u>2</u>	pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2	membrane & extracellular protein, Nuclear protein	
327	3.6E-05	1.2E-04	0.44	<u>238013</u> at <u>2</u>	pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2	membrane & extracellular protein, Nuclear protein	
575	3.3E-04	6.0E-04	0.44	<u>205499</u> at <u>SRPX2</u>	sushi-repeat-containing protein, X-linked 2	membrane & extracellular protein	
693	9.0E-04	1.4E-03	0.44	<u>230432</u> at <u>LOC553137</u>	hypothetical LOC553137		
124	3.5E-06	2.9E-05	0.43	<u>243951</u> at <u>ABCB1</u>	ATP-binding cassette, sub-family B (MDR/TAP), member 1	membrane & extracellular protein, Hypoxia and p53 in the Cardiovascular system, Multi-Drug Resistance Factors, Nuclear	

Receptors in Lipid Metabolism and Toxicity							
					carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9		
167	5.9E-06	3.7E-05	0.43	<u>224400_s_at</u>	<u>CHST9</u>	membrane & extracellular protein, Cysteine metabolism	
192	8.6E-06	4.7E-05	0.43	<u>201302_at</u>	<u>ANXA4</u>	annexin A4	
220	1.3E-05	6.3E-05	0.43	<u>207052_at</u>	<u>HAVCR1</u>	hepatitis A virus cellular receptor 1	membrane & extracellular protein
					pregnancy specific beta-1-glycoprotein 7 (gene/pseudogene)		
298	2.8E-05	9.9E-05	0.43	<u>205602_x_at</u>	<u>PSG7</u>	membrane & extracellular protein	
373	4.9E-05	1.4E-04	0.43	<u>220014_at</u>	<u>PRR16</u>	proline rich 16	
					cyclin-dependent kinase inhibitor 1C (p57, Kip2)		
499	1.8E-04	3.8E-04	0.43	<u>219534_x_at</u>	<u>CDKN1C</u>	Nuclear protein, Cell cycle, cell_cycle, immunology, tsnc	
526	2.1E-04	4.3E-04	0.43	<u>221916_at</u>	<u>NEFL</u>	neurofilament, light polypeptide	Amyotrophic lateral sclerosis (ALS)
581	3.4E-04	6.3E-04	0.43	<u>209866_s_at</u>	<u>LPHN3</u>	latrophilin 3	membrane & extracellular protein
593	3.7E-04	6.6E-04	0.43	<u>232099_at</u>	<u>PCDHB16</u>	protocadherin beta 16	membrane & extracellular protein
					solute carrier family 6 (neurotransmitter transporter, taurine), member 6		
86	1.9E-06	2.3E-05	0.42	<u>205920_at</u>	<u>SLC6A6</u>	membrane 6	membrane & extracellular protein

122	3.4E-06	2.9E-05	0.42	<u>235670</u> at	<u>STX11</u>	syntaxis 11	membrane & extracellular protein, SNARE interactions in vesicular transport
178	6.7E-06	4.0E-05	0.42	<u>212614</u> at	<u>ARID5B</u>	AT rich interactive domain 5B (MRF1- like)	Nuclear protein
188	8.3E-06	4.6E-05	0.42	<u>224221</u> s at	<u>VAV3</u>	vav 3 guanine nucleotide exchange factor	B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Focal adhesion, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Regulation of actin cytoskeleton, T cell receptor signaling pathway
303	2.9E-05	1.0E-04	0.42	<u>212099</u> at	<u>RHOB</u>	ras homolog gene family, member B	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes
319	3.5E-05	1.2E-04	0.42	<u>210195</u> s at	<u>PSG1</u>	pregnancy specific beta-1-glycoprotein 1	membrane & extracellular protein
372	4.8E-05	1.4E-04	0.42	<u>235836</u> at	<u>MXRA7</u>	matrix-remodelling associated 7	membrane & extracellular protein
387	5.9E-05	1.6E-04	0.42	<u>212148</u> at	<u>PBX1</u>	pre-B-cell leukemia homeobox 1	Nuclear protein, development, gene regulation, transcription
424	8.4E-05	2.1E-04	0.42	<u>204475</u> at	<u>MMPI</u>	matrix metallopeptidase 1 (interstitial collagenase)	membrane & extracellular protein, PPAR signaling pathway, angiogenesis

548	2.5E-04	4.8E-04	0.42	<u>206290</u> s at <u>RGS7</u>	regulator of G-protein signaling 7	Nuclear protein, cell_signaling, signal_transduction
608	4.2E-04	7.4E-04	0.42	<u>225660</u> at <u>A</u>	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A	membrane & extracellular protein, Axon guidance
76	1.6E-06	2.2E-05	0.41	<u>203159</u> at <u>GLS</u>	glutaminase	D-Glutamine and D-glutamate metabolism, Glutamate metabolism, Nitrogen metabolism, immunology
97	2.5E-06	2.7E-05	0.41	<u>225606</u> at <u>BCL2L1</u> 1	BCL2-like 11 (apoptosis facilitator)	membrane & extracellular protein
199	9.9E-06	5.3E-05	0.41	<u>209365</u> s at <u>ECM1</u>	extracellular matrix protein 1	membrane & extracellular protein
315	3.3E-05	1.1E-04	0.41	<u>218701</u> at <u>LACTB2</u>	lactamase, beta 2	membrane & extracellular protein, Synaptic Proteins at the Synaptic Junction, Cell adhesion molecules (CAMS)
379	5.3E-05	1.5E-04	0.41	<u>229649</u> at <u>NRXN3</u>	neurexin 3	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer- Genes
460	1.2E-04	2.7E-04	0.41	<u>1553962</u> s a <u>RHOB</u>	ras homolog gene family, member B	
528	2.2E-04	4.4E-04	0.41	<u>203951</u> at <u>CNN1</u>	calponin 1, basic, smooth muscle	
607	4.2E-04	7.3E-04	0.41	<u>209230</u> s at <u>NUPR1</u>	nuclear protein, transcriptional	Nuclear protein

					regulator, 1	
130	3.7E-06	3.0E-05	0.4	<u>243681</u> at <u>SHANK2</u>	SH3 and multiple ankyrin repeat domains 2	membrane & extracellular protein
179	6.8E-06	4.0E-05	0.4	<u>208106</u> x at <u>PSG6</u>	pregnancy specific beta-1-glycoprotein 6	membrane & extracellular protein
396	6.5E-05	1.7E-04	0.4	<u>212188</u> at <u>KCTD12</u>	potassium channel tetramerisation domain containing 12	membrane & extracellular protein
577	3.3E-04	6.0E-04	0.4	<u>244852</u> at <u>DSEL</u>	dermatan sulfate epimerase-like	membrane & extracellular protein
15	1.0E-07	6.6E-06	0.39	<u>208998</u> at <u>UCP2</u>	uncoupling protein 2 (mitochondrial, proton carrier)	membrane & extracellular protein, immunology, misc
30	3.0E-07	1.1E-05	0.39	<u>218806</u> s at <u>VAV3</u>	vav 3 guanine nucleotide exchange factor	B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Focal adhesion, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Regulation of actin cytoskeleton, T cell receptor signaling pathway
163	5.5E-06	3.6E-05	0.39	<u>212157</u> at <u>SDC2</u>	syndecan 2	membrane & extracellular protein, Perou's- Intrinsic- Breast-Cancer-Genes, Cell adhesion molecules (CAMs), ECM-receptor interaction,

							angiogenesis, metastasis
216	1.3E-05	6.3E-05	0.39	<u>205405</u> at <u>A</u>	<u>SEMA5</u> <u>A</u>	sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A	membrane & extracellular protein, Axon guidance
249	1.7E-05	7.2E-05	0.39	<u>213169</u> at <u>A</u>	<u>SEMA5</u> <u>A</u>	sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A	membrane & extracellular protein, Axon guidance
415	7.8E-05	2.0E-04	0.39	<u>203786</u> s at <u>1</u>	<u>TPD52L</u> <u>1</u>	tumor protein D52-like 1	
632	5.3E-04	8.9E-04	0.39	<u>225242</u> s at <u>CCDC80</u>		coiled-coil domain containing 80	membrane & extracellular protein
225	1.4E-05	6.6E-05	0.38	<u>231738</u> at <u>PCDHB7</u>	<u>7</u>	protocadherin beta 7	membrane & extracellular protein

240	1.6E-05	7.0E-05	0.38	<u>227095</u> at	<u>LEPR</u>	leptin receptor	v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)	Reversal of Insulin Resistance by Leptin, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway, Neuroactive ligand-receptor interaction, immunology
287	2.6E-05	9.5E-05	0.38	<u>209348</u> s at	<u>MAF</u>	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	Nuclear protein, tsonc	
480	1.4E-04	3.1E-04	0.38	<u>213182</u> x at	<u>CDKN1C</u>	Nuclear protein, Cell cycle, cell cycle, immunology, tsonc		
14	1.0E-07	6.6E-06	0.37	<u>49077</u> at	<u>PPME1</u>	protein phosphatase methylesterase 1	2,4-Dichlorobenzoate degradation, Alkaloid biosynthesis II, Butanoate metabolism	
95	2.5E-06	2.7E-05	0.37	<u>205533</u> s at	<u>CDH6</u>	cadherin 6, type 2, K-cadherin (fetal kidney)	membrane & extracellular protein, Nuclear protein	
140	4.1E-06	3.1E-05	0.37	<u>213624</u> at	<u>SMPDL3A</u>	sphingomyelin phosphodiesterase, acid-like 3A		
203	1.1E-05	5.5E-05	0.37	<u>210372</u> s at	<u>TPD52L1</u>	tumor protein D52- like 1	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	
272	2.3E-05	8.7E-05	0.37	<u>213348</u> at	<u>CDKN1C</u>	Nuclear protein, Cell cycle, cell cycle, immunology, tsonc		

274	2.3E-05	8.9E-05	0.37	<u>230163</u> at <u>GFRA1</u>	GDNF family receptor alpha 1	membrane & extracellular protein	
					sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A		
311	3.2E-05	1.1E-04	0.37	<u>229427</u> at <u>SEMA5</u> A	membrane & extracellular protein, Axon guidance		
675	7.8E-04	1.2E-03	0.37	<u>206167</u> s at <u>P6</u>	Rho GTPase activating protein 6	Rho cell motility signaling pathway	
28	3.0E-07	1.1E-05	0.36	<u>1555716</u> a a t	CXADR	coxsackie virus and adenovirus receptor	membrane & extracellular protein
					solute carrier family 6 (neurotransmitter transporter, taurine), member 6		
47	9.0E-07	1.9E-05	0.36	<u>205921</u> s at <u>SLC6A6</u>			membrane & extracellular protein
181	7.1E-06	4.1E-05	0.36	<u>202458</u> at <u>PRSS23</u>	protease, serine, 23	Nuclear protein, Perou's- Intrinsic-Breast-Cancer-Genes	
184	7.6E-06	4.4E-05	0.36	<u>208257</u> x at <u>PSG1</u>	pregnancy specific beta-1-glycoprotein 1	membrane & extracellular protein	

					solute carrier family 17 (sodium phosphate), member 3	membrane & extracellular protein
307	3.1E-05	1.1E-04	0.36	<u>207298</u> at <u>2</u>	<u>SLC17A</u> <u>2</u>	ST6 beta-galactosamide alpha-2,6-sialyltransferase 2
363	4.5E-05	1.3E-04	0.36	<u>228821</u> at <u>2</u>	<u>ST6GAL</u> <u>2</u>	membrane & extracellular protein
391	6.1E-05	1.7E-04	0.36	<u>232654</u> s at <u>NA</u>	<u>TMEM3</u> <u>7</u>	membrane & extracellular protein
448	1.1E-04	2.5E-04	0.36	<u>227190</u> at <u>NA</u>	<u>MMP7</u> <u>7</u>	membrane & extracellular protein
618	4.7E-04	8.0E-04	0.36	<u>204259</u> at <u>NA</u>	<u>SGCD</u> <u>7</u>	matrix metallopeptidase 7 (matrixins, uterine)
107	2.9E-06	2.9E-05	0.35	<u>228602</u> at <u>NA</u>	<u>SGCD</u> <u>7</u>	sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)
114	3.1E-06	2.9E-05	0.35	<u>225671</u> at <u>NA</u>	<u>SPNS2</u> <u>7</u>	spinster homolog 2 (Drosophila)
283	2.5E-05	9.5E-05	0.35	<u>225496</u> s at <u>NA</u>	<u>SYTL2</u> <u>2</u>	synaptotagmin-like 2
465	1.3E-04	2.9E-04	0.35	<u>232914</u> s at <u>NA</u>	<u>SYTL2</u> <u>2</u>	synaptotagmin-like 2
495	1.7E-04	3.6E-04	0.35	<u>228221</u> at <u>3</u>	<u>SLC44A</u> <u>3</u>	solute carrier family 44, member 3
						membrane & extracellular protein

				solute carrier family 23 (nucleobase transporters), member 1	membrane & extracellular protein, Vitamin C in the Brain
64	1.3E-06	2.1E-05	0.34	<u>223732</u> at <u>1</u>	<u>SLC23A</u>
40	7.0E-07	1.8E-05	0.33	<u>229441</u> at	<u>PRSS23</u>
82	1.8E-06	2.2E-05	0.33	<u>227276</u> at	<u>PLXDC2</u>
94	2.3E-06	2.6E-05	0.33	<u>203917</u> at	<u>CXADR</u>
118	3.3E-06	2.9E-05	0.33	<u>201212</u> at	<u>LGMN</u>
126	3.5E-06	2.9E-05	0.33	<u>203570</u> at	<u>LOXL1</u>
254	1.8E-05	7.4E-05	0.33	<u>229271</u> x at <u>1</u>	<u>COL11A</u>
343	4.1E-05	1.3E-04	0.33	<u>223204</u> at <u>B</u>	<u>FAM198</u>
350	4.2E-05	1.3E-04	0.33	<u>221748</u> s at	<u>TNS1</u>
408	7.3E-05	1.9E-04	0.33	<u>227598</u> at	<u>C7orf29</u>
454	1.1E-04	2.6E-04	0.33	<u>214587</u> at	<u>COL8A1</u>

512	1.9E-04	4.0E-04	0.33	<u>221805</u> at	<u>NEFL</u>	neurofilament, light polypeptide	Amyotrophic lateral sclerosis (ALS)
294	2.7E-05	9.6E-05	0.32	<u>205696</u> s at	<u>GFRA1</u>	GDNF family receptor alpha 1	membrane & extracellular protein
18	2.0E-07	8.8E-06	0.31	<u>217841</u> s at	<u>PPME1</u>	protein phosphatase methylesterase 1	2,4-Dichlorobenzoate degradation, Alkaloid biosynthesis II, Butanoate metabolism
88	2.1E-06	2.5E-05	0.31	<u>1556499</u> s a	<u>COL1A1</u>	collagen, type I, alpha 1	membrane & extracellular protein, Cell Communication, ECM-receptor interaction, Focal adhesion, immunology
111	3.0E-06	2.9E-05	0.31	<u>235774</u> at	<u>LOC553137</u>	hypothetical LOC553137	
191	8.3E-06	4.6E-05	0.31	<u>214606</u> at	<u>TSPAN2</u>	tetraspanin 2	membrane & extracellular protein
440	1.0E-04	2.5E-04	0.31	<u>206969</u> at	<u>KRT34</u>	keratin 34	Cell Communication
110	3.0E-06	2.9E-05	0.3	<u>229657</u> at	<u>THRB</u>	thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian)	Nuclear protein, Map Kinase Inactivation of SMRT Corepressor, Neuroactive ligand-receptor interaction, immunology, tsonc
174	6.4E-06	3.9E-05	0.3	<u>219250</u> s at	<u>ELRT3</u>	fibronectin leucine rich transmembrane protein 3	
233	1.5E-05	6.7E-05	0.3	<u>209738</u> x at	<u>PSG6</u>	pregnancy specific beta-1-glycoprotein 6	membrane & extracellular protein

					solute carrier organic anion transporter family, member 4C1	<u>SLCO4C</u> <u>1</u>	membrane & extracellular protein
310	3.2E-05	1.1E-04	0.3	<u>222071</u> s at <u>222071</u>			
344	4.1E-05	1.3E-04	0.3	<u>1559459</u> at <u>266</u>	<u>LOC613</u> <u>266</u>	hypothetical LOC613266	
13	1.0E-07	6.6E-06	0.29	<u>204437</u> s at <u>FOLR1</u>	folate receptor 1 (adult)	folate receptor 1 (adult)	membrane & extracellular protein, immunology
78	1.7E-06	2.2E-05	0.29	<u>226279</u> at <u>PRSS23</u>	protease, serine, 23		membrane & extracellular protein, Nuclear protein, Perou's- Intrinsic- Breast-Cancer-Genes
669	7.5E-04	1.2E-03	0.29	<u>204988</u> at <u>FGB</u>	fibrinogen beta chain		membrane & extracellular protein, Nuclear protein, Acute Myocardial Infarction, Extrinsic Prothrombin Activation Pathway, Fibrinolysis Pathway, Intrinsic Prothrombin Activation Pathway, Complement and coagulation cascades, immunology
8	< 1e-07	< 1e-07	0.28	<u>205380</u> at <u>PDZK1</u>	PDZ domain containing 1	PDZ domain containing 1	membrane & extracellular protein, Downregulated of MTA-3 in ER- negative Breast Tumors
73	1.6E-06	2.2E-05	0.28	<u>228716</u> at <u>THRB</u>	thyroid hormone receptor, beta (erythroblastic leukemia viral (v- erb-a) oncogene homolog 2, avian)	thyroid hormone receptor, beta (erythroblastic leukemia viral (v- erb-a) oncogene homolog 2, avian)	Nuclear protein, Map Kinase Inactivation of SMRT Corepressor, Neuroactive ligand-receptor interaction, immunology, tsnc

				KDEL (Lys-Asp-Glu-Leu) containing 1	KDELC1	membrane & extracellular protein
98	2.6E-06	2.8E-05	0.28	<u>219479</u> at		
353	4.2E-05	1.3E-04	0.28	<u>217478</u> s at	<u>NA</u>	membrane & extracellular protein
						Perou's- Intrinsic- Breast-Cancer-Genes, Cell adhesion molecules (CAMs), ECM-receptor interaction, angiogenesis, metastasis
44	9.0E-07	1.9E-05	0.27	<u>212154</u> at	<u>SDC2</u>	syndecan 2
						pregnancy specific beta-1-glycoprotein 9
280	2.5E-05	9.4E-05	0.27	<u>209594</u> x at	<u>PSG9</u>	membrane & extracellular protein
510	1.9E-04	4.0E-04	0.27	<u>232235</u> at	<u>DSEL</u>	dermatan sulfate epimerase-like
						membrane & extracellular protein, Acute Myocardial Infarction, Extrinsic Prothrombin Activation Pathway, Fibrinolysis Pathway, Intrinsic Prothrombin Activation Pathway, Complement and coagulation cascades, immunology
545	2.5E-04	4.8E-04	0.27	<u>216238</u> s at	<u>FGB</u>	fibrinogen beta chain
48	9.0E-07	1.9E-05	0.26	<u>227236</u> at	<u>TSPAN2</u>	tetraspanin 2
						membrane & extracellular protein
91	2.2E-06	2.5E-05	0.26	<u>212158</u> at	<u>SDC2</u>	syndecan 2
						Perou's- Intrinsic- Breast-Cancer-Genes, Cell adhesion molecules (CAMs), ECM-receptor interaction, angiogenesis, metastasis

176	6.6E-06	4.0E-05	0.26	<u>212094</u> at	<u>PEG10</u>	paternally expressed 10	Nuclear protein
258	1.9E-05	7.6E-05	0.26	<u>204320</u> at	<u>COL11A1</u>	collagen, type XI, alpha 1	membrane & extracellular protein, Cell Communication, ECM-receptor interaction, Focal adhesion
264	2.0E-05	8.0E-05	0.26	<u>221541</u> at	<u>CRISPLD2</u>	cysteine-rich secretory protein LCCL domain containing 2	membrane & extracellular protein
367	4.6E-05	1.3E-04	0.26	<u>156977</u> a a	<u>ZPLD1</u>	zona pellucida-like domain containing 1	membrane & extracellular protein
412	7.6E-05	2.0E-04	0.26	<u>227195</u> at	<u>ZNF503</u>	zinc finger protein 503	Nuclear protein
19	2.0E-07	8.8E-06	0.25	<u>232206</u> at	<u>ULK4</u>	unc-51-like kinase 4 (C. elegans)	
147	4.5E-06	3.2E-05	0.25	<u>222853</u> at	<u>ELRT3</u>	fibronectin leucine rich transmembrane protein 3	membrane & extracellular protein
182	7.2E-06	4.2E-05	0.25	<u>208191</u> X at	<u>PSG4</u>	pregnancy specific beta-1-glycoprotein 4	membrane & extracellular protein
72	1.6E-06	2.2E-05	0.24	<u>209493</u> at	<u>PDZD2</u>	PDZ domain containing 2	membrane & extracellular protein, Nuclear protein
376	5.2E-05	1.5E-04	0.24	<u>202435</u> s at	<u>CYP1B1</u>	cytochrome P450, family 1, subfamily B, polypeptide 1	membrane & extracellular protein, Metabolism of xenobiotics by cytochrome P450, Tryptophan metabolism, immunology,

							pharmacology
58	1.2E-06	2.1E-05	0.23	<u>227233</u> at	<u>TSPAN2</u>	tetraspanin 2	membrane & extracellular protein
257	1.9E-05	7.6E-05	0.23	<u>202436</u> s at	<u>CYP1B1</u>	cytochrome P450, family 1, subfamily B, polypeptide 1	membrane & extracellular protein, Metabolism of xenobiotics by cytochrome P450, Tryptophan metabolism, immunology, pharmacology
470	1.3E-04	3.0E-04	0.23	<u>230217</u> at	<u>CLVS1</u>	clavesin 1	
493	1.7E-04	3.6E-04	0.23	<u>1561969</u> at	<u>ZPLD1</u>	zona pellucida-like domain containing 1	membrane & extracellular protein
61	1.3E-06	2.1E-05	0.22	<u>206070</u> s at	<u>EPHA3</u>	EPH receptor A3	membrane & extracellular protein, Axon guidance, immunology, tsnc
150	4.8E-06	3.4E-05	0.22	<u>212651</u> at	<u>RHOBT</u> <u>B1</u>	Rho-related BTB domain containing 1	
116	3.2E-06	2.9E-05	0.21	<u>232752</u> at	<u>LOC100</u> <u>287616</u>	hypothetical protein LOC100287616	
129	3.6E-06	3.0E-05	0.21	<u>223928</u> s at	<u>GUCAL</u> <u>C</u>	guanylate cyclase activator 1C	Olfactory transduction
25	3.0E-07	1.1E-05	0.2	<u>223075</u> s at	<u>AIF1L</u>	allograft inflammatory factor 1-like	
87	2.1E-06	2.5E-05	0.2	<u>212092</u> at	<u>PEG10</u>	paternally expressed 10	Nuclear protein

256	1.8E-05	7.6E-05	0.2	<u>37892</u> at <u>1</u>	<u>COL11A</u> <u>1</u>	collagen, type XI, alpha 1	deleted in bladder cancer 1	FGF18, membrane & extracellular protein, Cell Communication, ECM- receptor interaction, Focal adhesion
224	1.4E-05	6.5E-05	0.19	<u>205818</u> at <u>DBC1</u>				membrane & extracellular protein, Metabolism of xenobiotics by cytochrome P450, Tryptophan metabolism, immunology, pharmacology
429	8.7E-05	2.2E-04	0.19	<u>202437</u> s at <u>CYP1B1</u>		cytochrome P450, family 1, subfamily B, polypeptide 1		
123	3.4E-06	2.9E-05	0.18	<u>202350</u> s at <u>MATN2</u>		matrilin 2	membrane & extracellular protein	membrane & extracellular protein, Complement and coagulation cascades
75	1.6E-06	2.2E-05	0.16	<u>213800</u> at <u>CFH</u>		complement factor H	membrane & extracellular protein, Complement and coagulation cascades	membrane & extracellular protein
79	1.7E-06	2.2E-05	0.16	<u>215388</u> s at <u>NA</u>		NA		membrane & extracellular protein
20	2.0E-07	8.8E-06	0.15	<u>204830</u> x at <u>PSG5</u>		pregnancy specific beta-1-glycoprotein 5		membrane & extracellular protein
330	3.7E-05	1.2E-04	0.15	<u>214930</u> at <u>SLTRK</u> <u>5</u>		SLIT and NTRK- like family, member 5		membrane & extracellular protein
39	7.0E-07	1.8E-05	0.12	<u>231867</u> at <u>ODZ2</u>		odz, odd Oz/ten-m homolog 2 (Drosophila)		membrane & extracellular protein
12	1.0E-07	6.6E-06	0.07	<u>1555564</u> a a <u>t</u>	<u>CFI</u> <u>1</u>	complement factor 1	Nuclear protein, Complement and coagulation cascades	membrane & extracellular protein

27	3.0E-07	1.1E-05	0.06	<u>203854</u> at	<u>CFI</u>	complement factor I	membrane & extracellular protein,
362	4.5E-05	1.3E-04	0.058	<u>1560851</u> at	<u>C10orf13</u>	chromosome 10 open reading frame 136	Nuclear protein, Complement and coagulation cascades

Filtering parameters:

Name of the project file: A224 FGF18 -Project -JustRMA.xls

Time of the analysis: Sat Dec 25 13:11:54 2010

BRB-ArrayTools Version: 4.1.0 - Beta_3 Release (October 2010)

Project annotated by Bioconductor (www.bioconductor.org) Dec 23 14:07:46 2010
annotation package hg13plus2.db(Version:2.4.1) on Thu

Spot Filters: OFF

Normalization: OFF

Exclude a gene under any of the following conditions:

Less than 20 % of expression data have at least a 1.5 -fold change in either direction from gene's median value
Percent of data missing or filtered out exceeds 50 %

Gene Subsets: OFF

Table S5. Primers for quantitative RT-PCR (5'-3').

	Forward	Reverse
FGF18 [#]	GACCTCCCGACGACAGAC	GATAGCAGCATCCTCCAGAACT
GAPDH [#]	ACCCACTCCTCCACCTTTG	CACCACCCCTGTTGCTGTAG
PPIA3 [#]	GCTTGCTGGCAGTTAGATGTC	AAATCCGCCACCTCTAGGATA
FGF18	TGCTTCCAGGTACAGGTGCT	GCTGCTTACGGCTCACATCG
AREG	ACGAACCACAAATACCTGGC	TTTCACTTCCCGTCTTGTGTTG
PLAT	CTGGAGAGAAAACCTCTGCG	GCAGAGCCCTCTCTTCATTG
PLAU	TGACCCACAGTGGAAAACAG	CCAGCTCACAAATTCCAGTCA
HMGA2	AAAGCAGAAGCCACTGGAGA	TCTTCGGCAGACTCTGTGA
CXCL1	GAAAGCTTGCCTCAATCCTG	CTTCCTCCTCCCTCTGGTC
CXCL2	GGGCAGAAAGCTTGTCTCAA	GCTTCCTCCTTCCTCTGGT
IL1A	TGTGACTGCCAACAGATGAAG	CTTAGTGCCGTGAGTTCCC
IL6	GCCACTCACCTCTCAGAAC	TGCCTCTTGCTGCTTCA
IL8	TCCTGATTCTGCAGCTCTGT	AAATTGGGGTGGAAAGGTT
VEGFC	TGTGTCCGTCTACAGATGT	GGCAGGAAGTGTGATTGG
TGM2	TCAGCTACAATGGGATCTTGG	CCGTAAGGCAGTCACGGTAT
CD73	ACTTCATGAACGCCCTGC	TTGGAAATTGGCCTCTTG
CFH	GCTGGTCTCCTACTCCCAGA	TTCGCTTTCTTTAAGGCA
CFI	GTGCTCCACTTAAGGTTTGC	TGGCAGAAGACTTATCGCA
MMP2	ATGCCGCCTTAACTGGAG	GGGAAGCCAGGATCCATTTC
MMP9	GGGACGCAGACATCGTCATC	TCGTCATCGTCGAAATGGGC
VEGFA	CACGAAGTGGTGAAGATTC	AGGATGGCTTGAAGATGT
IL10	GCTGTCATCGATTCTTCCC	CTCATGGCTTGTAGATGCCT
IL12A	TCAGCAACATGCTCCAGAAG	CCTCCACTGTGCTGGTTTAT
IL1B	GAAGCTGATGGCCCTAAACA	AAGCCCTGCTGTAGTGGTG
CCL2	GTCTCTGCCGCCCTCTGTG	AGGTGACTGGGCATTGATTG
FGFR1	GTCACAGCCACACTCTGCAC	GGAAGGACTCCACTTCCACA
FGFR2	CGGCCCTCCTCAGTTAGT	CGCAGCCACGTACACTTCT
FGFR3	GTCCTGGGGACGGAGC	TCAGCTCCACAGCATCCC
FGFR4	CTGACCAAGCCAGCACTGT	CTTCATCACCTCCATCTCCG
GAPDH	GAAGGTGAAGGTCGGAGTC	CATGTAGTTGAGGTCAATGAAGG
PPIA	CACCGTGTCTCGACATTG	TCCTTCTCTCCAGTGCTCAG
ACTB	GCACAGAGCCTCGCCTT	GTTGTCGACGACGAGCG

Primers used for microarray validation (the 53-tumor panel).